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81. INTRODUCTION
The long-term follow-up of preterm infants with or without diagnosed chronic lung disease
(CLD) is an ongoing saga. The history of this chronic lung disorder is relatively young,
having been described a little more than 30 years ago (Northway et al 1967). When Northway
et al (1990) reported a long-term follow-up of infants with CLD, the results were surprisingly
good, indicating mild bronchial obstruction and increased bronchial responsiveness. These
findings have been confirmed by other studies. Bronchial obstruction, hyperresponsiveness
with mild respiratory symptoms regardless of CLD are common in schoolchildren born
preterm (Gross et al 1998). However, the results of these long-term studies on a cohort of
children inform us about the effect of a particular therapeutic approach that may have
completely changed by the time the study is completed. During the 1970s, continuous
positive airway pressure and positive end expiratory pressure were introduced. In the late
1980s, surfactant replacement therapy again changed the population of surviving infants. The
influence of this therapy on the long-term prognosis has not been studied. Antenatal and
prenatal steroid therapy may also have an effect on long-term lung function. Today, infants
born after 30-32 weeks of gestation and ventilated for respiratory disease only exceptional die
or develop CLD. The average surviving preterm baby with CLD is therefore more premature
than previously. This may lead to increased severity of pulmonary disease and a poorer
outcome in spite of the rapid advances in neonatal care.
In schoochildren born preterm the causes of abnormal lung function are complex. Impaired
airway growth in infancy, smooth muscle hypertrophy, peribronchial and bronchial fibrosis,
and pathological changes in the bronchial mucosa have been suggested (Marcgraft et al 1991,
Chan et al 1993). Neutrophilic inflammation plays a prominent role in the pathophysiology of
early CLD in preterm infants (Merritt et al 1983, Yoder et al 1991). It is not known whether
chronic inflammation plays a role in the increased bronchial responsiveness of schoolchildren
born very preterm, as it does in asthma or whether these changes are responsive to treatment.
The beneficial effect of glucocorticoids (GC) on lung disease has been demonstrated in
ventilator-dependent neonates (Yoder et al 1991, Bhuta and Ohlsson 1998, Cole et al 1999)
and in some wheezy preterm infants (Yuksel et al 1992b). There has been one report of short-
9term treatment with inhaled GC at school age. This treatment did not influence basic lung
function or bronchial responsiveness in children born preterm (Chan et al 1993). 
With the aim of evaluating basic lung function, respiratory symptoms, bronchial lability and
bronchial responsiveness in every-day life in schoolchildren born very preterm and any
findings suggesting inflammatory lung disease, we studied a total of 63 schoolchildren born
very preterm. Our aim was also to investigate the lung function of a cohort of children who,
as small preterm infants, participated in randomized trials of surfactant therapy in order to
assess the effect of surfactant. In order to evaluate bronchial lability in these children, we
used a novel data storage home spirometer. 
10
2. REVIEW OF THE LITERATURE
2.1. Lung function during infancy in children born preterm
2.1.1. The premature lung and respiratory distress syndrome
The lungs of preterm infants are both structurally and functionally immature. With premature
birth, normal lung growth and development are disrupted and the immature lung is exposed to
adverse stimuli at the time when it is most susceptible to injury related to oxidants,
barotrauma and/or infection-inflammation. Lung structural development may be divided into
the following five phases (Langston et al 1984). 1. The embryonic period, formation of
proximal airways, bronchi, (4 to 6 weeks) 2. The glandular period, formation of conducting
airways, bronchioles, (7 to 16 weeks),  3. The canalicular period, formation of acini, the
structural development of the alveolar-blood barrier, (17 to 27 weeks), 4. The saccular period,
expansion of the gas-exchange units, primitive alveoli, (28 to 35 weeks), and 5. The alveolar
period: expansion of surface area due to formation of true alveoli (36 to 3 years post-term).
Functionally during foetal life, gas-exchange is performed by the placenta and a fluid fills the
developing future airspaces until birth. Surfactant synthesis in type II alveolar cells begins to
increase at 20 weeks of gestation (Hansen and Corbet 1998). In infants of early gestational
age, there is clearly a difference in the maturational level of the lung. Lung maturation does
not depend only on gestational age. Genetic factors and several pharmacological effectors
(prolactin, glucocorticoids, sex hormones, insulin and catecholamines) associated with
complications of pregnancy modify the normal timing of lung maturation (Merkus et al
1996). Collagen is the major connective tissue element of non-respiratory component of lung.
Elastin predominates in the gas-exchanging lung parenchyma. In newborn infants, elastic
recoil is low because of sparse elastic fibres. After birth, the elastic content of the elastin
fibres increases rapidly to reach adult levels by 6 months of age (Keeley et al 1977). Impaired
respiratory mechanics including an elastic rib cage, insufficient connective tissue of
conductive airways and incomplete development of the terminal air spaces and the pulmonary
capillary bed compared with full-term newborns impair lung function after preterm birth and
make the immature lung vulnerable to mechanical damage (Langston et al 1984, Hansen and
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Corbet 1998). In addition to surfactant deficiency, the immature lung lacks adequate
antioxidant defence systems and there is imbalance of the protease-antiprotease system, and
these render the lung more vulnerable to the toxic effects of oxygen (Hansen and Corbet
1998). 
A preterm infant with surfactant deficiency may develop respiratory distress syndrome
(RDS). The primary reason for the RDS is surfactant deficiency, caused by lower absolute
amounts or by abnormal composition and function of the surfactant. The incidence of RDS is
60% at 29 weeks´gestation but declines with maturation to near 0 by 39 weeks. On
histological examination, the peripheral air spaces are collapsed, respiratory bronchioles lined
with necrotic epithelium and hyaline membranes have an overdistended appearance. There is
obvious pulmonary oedema with congested capillaries, amd the lymphatic and interstitial
spaces are distended with fluid. Reduced lung compliance (CL), reduced functional residual
capacity of the lung (FRC) and disturbed gas diffusion, but no increase in airway resistance
(Raw), are the functional features of the RDS (Hansen and Corbet 1998). 
RDS is by far the most common cause of acute lung injury and respiratory failure in the small
preterm infants (birth weight @ 1500 g). However, extreme immaturity itself, patent ductus
arteriosus, apnoeic spells, aspiration, pulmonary infections, and condition worsening the
general condition of neonate (e.g. severe asphyxia, intracranial haemorrhage, necrotizing
enterocolitis, septicaemia) can also lead to respiratory insufficiency necessitating ventilatory
support (Hansen and Corbet 1998). The degree of acute lung injury superimposed at a stage
of incomplete lung development seems to play an important role in determining the severity
of acute respiratory distress and whether bronchopulmonary dysplasia (BPD) or chronic lung
disease (CLD) will develop.
  
2.1.2. Bronchopulmonary dysplasia and chronic lung disease of the newborn
As first characterized by Northway (1967) in a report on 32 infants, BPD is a chronic
cardiopulmonary disease of infancy that follows ventilator and oxygen therapy for neonatal
respiratory distress. In his initial report, Northway (1967) proposed that oxygen toxicity plays
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a major role in the pathogenesis of BPD. Some other investigators, however, emphasized the
role of intermittent positive pressure ventilation as the cause of BPD (Taghizadeh and
Reynolds 1976). Since this initial description of Northway (1967), much has been learned
about the pathogenesis, pathophysiology and outcome of BPD and it has been realized that
BPD may also occur in infants who have not previously had RDS (Bancalari et al 1979,
Koops et al 1984, O´Brodovich and Mellins 1985, Merritt et al 1988, Greenough 1990a,
Holzman and Frank 1992, Northway 1992, Rojas et al 1995).
 
For purposes of uniform reporting, the initial definition of BPD of Bancalari (1979) was
changed to a definition of disturbed gas exchange in an infant requiring oxygen at more than
28 days after birth (Sinkin 1990). However, this definition has become less useful because of
the survival of infants at ever-lower gestational ages. This definition includes a wide range of
infants, from those who ultimately appear to have no residual problems at one extreme to
those with severe BPD, as described by Northway (1967). A more practical definition would
be respiratory sequelae in an infant who is dependent on supplementary oxygen at 36 weeks´
postconceptional age (Shennan et al 1988). Using this definition showed that extending the
time period to 36 weeks´ postconceptional age improves the predictive power of
supplementary oxygen dependence (Shennan et al 1988). A recent study indicates that
radiographic evidence consistent with BPD was more predictive of long-term respiratory
outcome than other commonly used criteria (Palta 1998). However, differences in diagnostic
criteria of BPD between hospitals and physicians cannot easily be eliminated, and population-
based studies of neonatal outcome and studies of incidence are especially difficult to
compare. 
The incidence of BPD is generally reported at 20% of ventilated newborns, but wide
variability exists between centers because of differences between populations and
managements (Harrod et al 1974, Bancalari et al 1979, Avery et al 1987, Sinkin et al 1990,
Abman and Groothius 1994). The incidence is inversely related to birth weight, being as high
as 85% of neonates between 500-699 g but decreasing to 5% in infants with birthweights over
1500 g (Avery et al 1987, Parker et al 1992). With the survival of  increasing numbers of
infants of 24 to 26 weeks´ gestation, the numbers of infants with significant BPD have also
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risen markedly (Zimmerman and Farrell 1994). 
Pathological stages: Northway et al (1967) divided the clinical, radiological, and pathological
progression of BPD into four stages. Stage 1 (at 1 to 3 days of age) consisted of the initial
picture of RDS and revealed marked alveolar and interstitial oedema with hyaline
membranes, atelectasis and necrosis of the bronchial mucosa. During stage 2 (at 4 to 10 days
of age), atelectasis becomes more extensive, alternating with areas of emphysema. There is
widespread necrosis and repair of bronchial mucosa. Cellular febris fills the airways. There is
increasing opacification of the lungs. Stage 3 (at 11 to 30 days) is a transition period to
chronic lung disease with radiological changes characteristic of interstitial fibrosis,
emphysematic areas and atelectasis foci. Extensive broncial metaplasia and hyperplasia
evolve. This stage could be complicated by patent ductus arteriosus (PDA) and congestive
heart failure. During stage 4 (after 30 days of age) there is massive fibrosis of the lung with
destruction of alveoli and airways. There is hypertrophy of bronchial smooth muscle,
metaplasia of airway mucosa, and actual loss of pulmonary arterioles and capillaries and
medial muscular hypertrophy of remaining vessels. The electrocardiogram at this stage
usually shows right ventricular hypertrophy and cardiomegaly with cor pulmonale (Northway
et al 1967). Today, the term chronic lung disease of prematurity is used widely instead of
BPD (Hudak et al 1992). Sometimes the term BPD is used to represent only the more severe
end (Northway stage IV) of the spectrum of chronic lung disease in infants born preterm
(Greenough 1990a). The term CLD, used to describe the aftermath of preterm birth and its
treatment, is deliberately vague (Kotecha and Silverman 1999). CLD is currently a widely
used definition to embrace both a range of well-characterized syndrome and an overall
increase in respiratory tract morbidity in infancy and later life.
Etiology and pathogenesis: Premature birth is associated with immature lung structure, lack
of surfactant, and inadequate respiratory drive, all of which contribute to respiratory failure.
In the multifactorial pathogenesis of CLD, respiratory failure is critical because it requires
treatment with supplementary oxygen and artificial ventilation. CLD represents the
developing lung´s response to acute lung injury and altered repair processes. The principal
factors in the pathogenesis of CLD are genetic predisposition, immaturity of the lung, which
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contributes to chronic pulmonary insufficiency of prematurity, oxygen toxicity, barotrauma,
inflammation, pulmonary oedema and PDA and perhaps infection (Merrit et al 1988,
O´Brodovich and Mellins 1985, Abman and Groothius 1994, Watterberg et al 1996, Hansen
and Corbet 1998). These factors induce typical histological features of CLD. Marked airway
changes, such as squamous metaplasia of large and small airways, increased peribronchial
smooth muscle with fibrosis, chronic inflammation, and submucosal oedema with
hypertrophied submucosal glands. Parenchymal disease is characterized by volume loss from
atelectasis and alveolar septal fibrosis alternating with regions of hyperinflation and
emphysema. The number of alveoli is markedly diminished, the internal surface area of the
lung is decreased and lung volume is diminished (Bonikos et al 1976, Sobonya et al 1982,
Stocker 1986, Marcgraft et al 1991). This is associated with decreased numbers of small
pulmonary arteries. Structural changes in the pulmonary circulation include intimal
proliferation, smooth muscle hypertrophy and advential thickening (Tomashefski et al 1984,
Hislop and Haworth 1990). 
Although, many aspects of CLD following neonatal intensive care have changed since
Northway´s classic description, high morbidity and mortality persist, although there are
changing trends in the epidemiology and pathogenesis of neonatal CLD. New therapies, such
as administration of exogenous surfactant (Pramanik et al 1993), high frequency ventilation
(HiFi study group 1990), pre- and postnatal steroids and other changes in patient care may
have altered the severity of CLD, but CLD still remains a major clinical problem. With
continued improvement in the survival of extremely preterm newborns, CLD remains one of
the most significant sequelae of neonatal intensive care. One recent study suggested that
much of the increase in the incidence of CLD may be because of improved survival (Parker et
al 1992). In recent years, less severe forms of CLD have frequently been observed  in infants
with mild or no initial RDS (Heneghan et al 1986, Parker et al 1992, Rojas et al 1995). This
change in clinical pattern suggests that, in these infants, risk factors different from those
associated with the severity of the initial respiratory course are responsible for the
development of CLD (Merth et al 1997). It also suggests a different aetiology for CLD in the
smallest babies (<700 g), who have a high risk of CLD without antecedent acute pulmonary
disease and need prolonged mechanical ventilation (Kotecha and Silverman 1999)
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2.1.3. Abnormalities of lung function during infancy in children born preterm
The most prominent lung function abnormalities in preterm born infants with CLD are
increased Raw and decreased specific airway conductance (SGaw) (Ahlström 1975, Stocks et al
1978, Morray et al 1982, Goldman et al 1983, Lindroth and Mortensson 1986, Gerdhard et al
1987, Motoyama et al 1987, Hifi Study 1990, Lebourges et al 1990, Yuksel et al 1991, Van
Lierde et al 1994, Baraldi et al 1997) and bronchial hyperreactivity (BHR) (Motoyama et al
1987). Initially low SGaw reaches the range of normality by the age of 2-3 years (Bryan et al
1973, Gerdhard et al 1987, Baraldi et al 1997). As defined by responsiveness to
bronchoconstrictor (methacoline, histamine, cold air) challenges, BHR persists in older
children and adolescents with a history of CLD (Smyth et al 1981, Morray et al 1982, Bader
et al 1987, Andreasson et al 1989, Kleine et al 1990, Northway et al 1990, Blayney et al 1991,
Mallory et al 1991). Pulmonary function measurements have also characterized other
abnormalities of lung mechanics, including increased dead space ventilation, decreased CL,
maldistribution of ventilation, increased work of breathing and abnormal ventilation-
perfusion matching (Hansen and Corbet 1998). Serial studies during infancy and early
childhood demonstrate that lung volumes (FRC) are decreased in early infancy but increase
with time (Bryan et al 1973, Gerdhard et al 1987, Baraldi et al 1997) probably by formation
of new alveoli. Some investigators have not found increased FRC during late infancy (Tepper
et al 1986). Total respiratory system compliance is lower in CLD infants than in controls,
probably reflecting mechanical alteration in the lung´s elastic properties (Stocker 1986) and
loss of lung tissue (Van Lierde et al 1994), but has a tendency to normalize with advancing
age (Bryan et al 1973, Ahlström 1975, Stocks and Godfrey 1976, Baraldi et al 1997). Preterm
infants with RDS but without CLD may also have abnormal lung function (Wong 1982,
Yuksel and Greenough 1992a, Merth et al 1997). 
However, although pulmonary mechanics in CLD survivors tends to improve during the early
years of life, reaching the range of normal values, 70% of these children still show abnormal
lung function when this is evaluated from forced expiratory flow by the squeeze technique at
2 years of age (Tepper et al 1986, Baraldi et al 1997). These findings support the prediction
that early injury to the airways tends to persist in infancy (Motoyama et al 1987) and
16
represents a risk factor for obstructive airway disease later in childhood and adolescence
(Northway et al 1990).
 2.2. Abnormalities of lung function in schoolchildren born preterm
 
Although many abnormalities of pulmonary function in preterm born infants can improve
with age (Gerdhard et al 1987, Mallory et al 1991, Blayney et al 991, Koumbourlis et al 1996,
Baraldi et al 1997) there is increasing evidence that respiratory problems persist into late
childhood and early adolescence. 
2.2.1. Basic lung function
Abnormal spirometric values, indicating bronchial obstruction, have been reported by several
investigators in schoolchildren born preterm with a history of CLD (Smyth et al 1981, Bader
et al 1987, Andreasson et al 1989, Northway et al 1990, Kleine et al 1990, Hakulinen et al
1990, Blayney et al 1991, Parat et al 1995, Hakulinen et al 1996, Koumbourlis et al 1996,
Jacob et al 1997, Jacob et al 1998). The largest study so far is a group of preterm children
with CLD monitored by Gross et al (1998). At 7 years of age the 43 children with a history of
CLD had more airway obstruction, i.e. significantly reduced forced vital capacity (FVC),
forced expiratory volume in one second (FEV1) and forced expiratory flow at 50-75% of vital
capacity (FEF25-75) values, than either 53 preterm children without a history of CLD or 108
children born at term. Increased residual volume of the lung and total lung capacity ratios
(RV/TLC) or elevated FRC, indicating air-trapping, is a common finding in children with a
history of CLD (Smyth et al 1981, Bader et al 1987, Andreasson et al 1989, Northway et al
1990, Hakulinen et al 1990, Blayney et al 1991, Koumbourlis et al 1996, Jacob et al 1998).
Those children with the greatest degree of airflow limitation and air-trapping had the greatest
abnormalities in both the shape and position of the pressure volume curves of the lung (Jacob
et al 1998).
The long-term pulmonary outcome in preterm children with a history of RDS but without a
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history of CLD is less clear. In earlier studies, children with histories of RDS had normal
pulmonary function by school age (Lamarre et al 1973, Stahlman et al 1982). In studies in
which children with more immature lung have been followed, reduced flow and SGaw values
and elevated RV/TLC ratios have been found in ventilator-treated children at school age
compared to controls born at term  (Bertrand et al 1985, Galdes-Sebaldt et al 1989, Chan et al
1989c, Lebourges et al 1990, Kleine et al 1990, Hakulinen et al 1996, Jacob et al 1997). Cano
and Payo (1997) found that children born preterm with RDS but without CLD at the age of 11
years had significantly reduced flow values and a significantly higher Raw compared with
those children without RDS, not ventilated for other causes, and matched for gestational age.
In contrast, among preterm born schoolchildren without previous CLD, but RDS in 38% of
these children, Gross et al (1998) found that lung function was similar to that of the term
control group. 
Prematurity alone is also assumed to be a risk factor for abnormal lung function in childhood.
Studies of preterm born schoolchildren without significant respiratory disease have shown
reduced FEV1, FEF50-25 , SGaw values, and abnormal lung mechanics (Coates et al 1977,
Bertrand et al 1985, Mansell et al 1987, Galdes-Sebaldt et al 1989, Parat et al 1995). Galdes-
Sebaldt et al (1989) and Bertrand et al (1985) found increased RV/TLC ratio in those
children. Chan et al (1989c) reported that their preterm born children had reduced FEV1
values at 7 years of age, irrespective of whether they had required ventilation in the neonatal
period. In contrast, Northway et al (1990) found that the pulmonary function of their preterm
born control children who had not undergone mechanical ventilation had lung function
similar to that of controls born at term. In a recent large, population-based Scottish study of
300 very low birth weight (VLBW) children of 8 to 9 years of age, FVC was more affected
than expiratory function (McLeod et al 1996). In contrast, Kitchen et al (1992) reported that
in their VLBW population there was little evidence of impared lung function at 8 years.     
 
The effect of intrauterine growth on lung function at school age is controversial. In a large
study of schoolchildren throughout the United Kingdom, Rona et al (1993) reported that birth
weight for gestational age, i.e. intrauterine growth, was significantly associated with FVC and
FEV1 after taking gestational age, parental smoking, and social factors into account. In
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contrast, McLeod et al (1996) concluded that poorer lung function of their VLBW population
is associated with very low birth weight, but not with intrauterine growth retardation. In their
population, 34% of children were small for gestational age but did not have reduced lung
function as compared with appropriately grown VLBW children. Thus, they could not
confirm the association of obstructive airway disease with intrauterine growth retardation
reported in some studies (Barker et al 1991, Rona et al 1993, Nikolajev et al 1998). Matthes
et al (1995) also reported that low birth weight at term was not associated with reduced lung
function in adolescents.
2.2.2. Response to β2 agonist and to the bronchial provocation tests
Although many schoolchildren born preterm may have airway obstruction regardless of CLD,
there may be a reactive component, as indicated by the bronchodilator response in some
subjects. In a recent study, 57% of all children, not only those with a history CLD but also
preterm children without a history of CLD in the control group, showed a significant response
to bronchodilation (Jacob et al 1998). Gross et al (1998) observed bronchodilator
responsiveness twice as often in preterm children with previous CLD (47%) as in preterm
children without a history of CLD (25%). However, they did not test bronchodilator
responsiveness in all children irrespective of spirometry results. In earlier studies at least half
the preterm born schoolchildren with a history of CLD had significant bronchodilator
responsiveness (Smyth et al 1981, Andreasson et al 1989, Northway et al 1990, Kleine et al
1990, Koumbourlis et al 1996). In addition, some children born preterm without a history of
CLD may have had a significant bronchodilator response (Andreasson et al 1989).
Increased incidence of BHR, as demonstrated by positive methacoline or histamine
challenges, has been observed in children born preterm, irrespective of their RDS or CLD
status (Bertrand et al 1985, MacLusky et al 1986, Riedel 1987, Chan et al 1988, Chan et al
1989a, Galdes-Sebaldt et al 1989). Cano and Payo (1997) found BHR in 35% of preterm born
children with previous RDS but without a history of CLD and in 23% in children without
RDS, but they did not have a control group born at term. In studies of a group of children
with a history of CLD, the majority of children had BHR (Smyth et al 1981, Bader et al 1987,
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Blayney et al 1991, Koumbourlis et al 1996). Northway et al (1990) also found that adults
with a history of CLD had BHR, but their preterm control group did not differ from their
control group born at term. Although lung function abnormalities in children with a history of
CLD may improve with age, BHR persists (Blayney et al 1991). Duiverman et al (1988)
found normal bronchial responsiveness in 3- to 10-year-old preterm born children tested by
the forced oscillation technique.
2.2.3. Diffusing capacity
Smyth et al (1981) measured the pulmonary diffusing capacity of carbon monoxide (DLCO) in
five children with a history of CLD aged 7-9 years and found normal results. Galdes-Sebaldt
et al (1989) found significantly decreased DLCO values in 11- to 13-year-old children with birth
weights of < 1500 g who had suffered from neither RDS nor CLD. Northway et al (1990)
found slightly lowered DLCO values in young adults with a history of CLD. In a Finnish study,
DLCO values in preterm born children both with and without a history of CLD were
significantly lower than those in controls born at term (Hakulinen et al 1996). However, the
diffusing capacity per effective alveolar volume (DL/VA), did not differ significantly between
the groups (Hakulinen et al 1996). In a recent study, no significant difference in DLCO, either
uncorrected or corrected for lung volumes, was found in subjects with a history of CLD as
compared with a preterm born group without a history of CLD (Jacob et al 1998). However,
these values were not compared with a term control group.  
2.2.4. Testing during exercise
In several studies it has been observed that even children with a history of severe CLD did not
differ from either preterm or term-born control children in their maximal work capacity or
maximal oxygen consumption (Bader et al 1987, Andreasson et al 1989, Parat et al 1995,
Jacob et al 1997, Gross et al 1998). However, children with CLD used a greater percentage of
their ventilatory reserve. These children were also more likely than control children to have
oxygen desaturation during exercise, and this was most evident in children with markedly
reduced values for FEV1 (Jacob et al 1997). Bader et al (1987) found that exercise-induced
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bronchospasm occurred in 50% of the CLD group but not in the control group born at term
indicating BHR.
Some investigators have found a significant correlation between current measures of reduced
airflow and the duration of mechanical ventilation or the time on supplementary oxygen
(Stahlman et al 1982, Arad et al 1987, Bader et al 1987, Andreasson et al 1989, Jacob et al
1998). Some have failed to find any such association (MacLusky et al 1986, Chan et al 1989c,
Galdes-Sebaldt et al 1989, Hakulinen et al 1996, Cano and Payo 1997). Chan et al (1989c)
found a strong correlation between birth weight and FEV0.75 at 7 years of age in agreement
with several other studies (Bader et al 1987, Mansell et al 1987, Galdes-Sebaldt et al 1989).
Male sex was also independently associated with reduced FEV0.75 (Chan et al 1989c). Birth
weight was observed to be associated with DLCO values at school age (Galdes-Sabaldt et al
1989, Hakulinen et al 1996)
2.3. The role of inflammation in the pathogenesis of abnormal lung function 
2.3.1. In children born preterm 
There is growing evidence suggesting that an inflammatory pulmonary reaction following
lung trauma may be an early event in the course of CLD, finally leading to lung fibrosis
(Groneck and Speer 1995). Inflammation includes production of chemotactic factors in
response to a specific stimulus (trauma, hypoxia/reperfusion, hyperoxia), migration of
inflammatory cells, increased expression of adhesion molecules on endothelial and epithelial
cells, adhesion of neutrophils, secretion of proteases and toxic oxygen radicals and increased
microvascular permeability (Groneck and Speer 1995). In response to a primary form of
injury, oxygen toxicity or volutrauma, there is an inflammatory response (Merritt et al 1981,
Odgen et al 1984, Pierce and Bancalari 1995) which is reflected in increased numbers of
neutrophils in the bronchial lavage samples as early as the second day of life (Odgen et al
1984, Arnon et al 1993). In the bronchial lavage sample, the neutrophil count peaks on the
fourth day of life and then declines rapidly to normal by the end of the first week in those who
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recover from RDS but declines much more slowly in those who go on to develop CLD
(Odgen et al 1984). In parallel to the neutrophil influx, the chemotactic activity of
tracheobronchial aspirate fluid is increased in infants developing CLD (Groneck et al 1994).
In the bronchial lavage samples during the first week, there are elevated levels of mediators
and cytokines, such as leukotrienes, platelet-activating factor, fibronectin, fibroblast-
activating factors and others (Groneck and Speer 1995, Hansen and Corbet 1998); elevated
levels of interleukins, especially interleukin-8 (Groneck et al 1994, Kotecha et al 1995,
Munshi et al 1997); and in one of the earliest responses to injury, markedly elevated levels of
interleukin-6 in bronchial lavage samples on the first day of life in those destined to develop
CLD (Bagchi et al 1994). Recruitment of neutrophils to the lung is thought to occur via
interactions occurring between adhesion molecules on the surfaces of endothelial cells and
neutrophils; increased concentrations of the adhesion molecules have been found in the
tracheal aspirates of infants with early CLD (Kotecha et al 1995).  
High levels of neutrophil elastase and desmosine (a degradation product of elastin) were
found in airway specimens of infants with CLD (Merritt et al 1983, Bruce et al 1985, Speer et
al 1993, Groneck and Speer 1995) and the activity of an important antiprotease was low
(Odgen et al 1984). An imbalance between protease and antiprotease activity was therefore
suggested to be an important mechanism of lung damage in CLD. The ratio of elastase to
secretory leucocyte protease inhibitor was higher in infants who developed CLD than in
controls, suggesting an unfavourable balance (Merritt et al 1983, Watterberg et al 1994a). At
present there is only an association between pulmonary inflammation and microvascular
permeability, one of the most important pathophysiological factors of early CLD; clear
causality has not proved (Groneck and Speer 1995). In infants who do not develop CLD, the
neutrophils undergo programmed cell death (apoptosis) and are ingested by macrophages
without releasing their elastases or other destructive enzymes (Grigg et al 1991); this process
may be disturbed in those who develop CLD. Studies have also reported not only persistent
elevation of neutrophils but also activated alveolar macrophages in the tracheal fluid effluent
of infants with CLD (Groneck and Speer 1995). In children with CLD in whom
bronchoalveolar lavage was performed at a mean age of 4 months, alveolar macrophages
represented 90% of the cell population (Clement et al 1988). Activated macrophages can
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produce oxygen free radicals and excess fibronectin, which is a potent chemoattractant and
growth factor for fibroblasts. Overstimulation of the repair response with increased
production of cellular fibronectin is associated with the development of pulmonary fibrosis,
which is prominent in infants who die of CLD (Pierce and Bancalari 1995). In recent studies
it has been suggested that, in CLD, eosinophils also participate in the inflammatory process
(Yamamoto et al 1996, Raghavender and Smith 1997). 
It is assumed that these early inflammatory changes in ventilator-dependent neonates and
subacute inflammatory changes in wheezy preterm infants are important pathological
features contributing to the abnormal lung function findings. In contrast, it is suggested that
abnormalities of pulmonary function and increased BHR in preterm born schoolchildren are
not solely an effect of chronic bronchial inflammation but are due to abnormal changes in
pulmonary structure (Chan and Silverman 1993). Although the abnormalities of pulmonary
function are similar to those seen in asthma, on the ground of the response to GC treatment it
is suggested that chronic bronchial inflammation does not play a part in these changes (Chan
and Silverman 1993). 
2.3.2. In adults with asthma or with chronic obstructive pulmonary disease  
Eosinophil-mediated damage to the respiratory epithelium is a major pathogenetic mechanism
in asthma (Bousquet et al 1990). Activated eosinophils secrete several granule-derived
proteins, e.g. eosinophil cationic protein (ECP) (Venge 1994), which is increased in asthma
(Bousquet et al 1990, Lacoste et al 1993). In chronic obstructive pulmonary disease (COPD)
of adults, neutrophils are prominent in the airways (Lacoste et al 1993). Activated neutrophils
secrete several proteins including myeloperoxidase (MPO) (Venge 1994), which is increased
in bronchoalveolar lavage fluid in COPD (Lacoste et al 1993). 
Numerous studies have shown that lymphocytes also play an important role in the
pathogenesis of asthma (Azzawi et al 1990, Robinson et al 1991) and also in COPD
(O´Shaughnessy et al 1997, De Jong et al 1997). In adults with mild to severe asthma, both
activated T cells (activated CD4+ T lymphocytes, as reflected by an increase in the expression
of CD25) and activated eosinophils have been observed in bronchial biopsies (Bousquet et al
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1990,  Azzawi et al 1990) in bronchoalveolar lavage (BAL), and in the peripheral blood of
adult patients (Bousquet et al 1990, Robinson et al 1991, Wilson et al 1994). The degrees of
T-lymphocyte activation and eosinophilia were closely correlated with the severity of the
asthma and the degree of bronchial responsiveness (Bousquet et al 1990, Azzawi et al 1990,
Robinson et al 1991). Further, the percentages of activated T cells decreased with inhaled GC
treatment (Wilson et al 1994). These findings suggest that T-cell activation and eosinophil
recruitment represent a pathway leading to the development of airway narrowing,
hyperresponsiveness, and symptoms of atopic asthma (Bousquet et al 1990, Azzawi et al
1990, Robinson et al 1991, Wilson et al 1994). 
However, there have been few studies on the pathogenesis of childhood asthma. The
properties of peripheral blood cells in asthmatics closely resemble those of cells in the
bronchial mucosa and BAL fluid, suggesting that peripheral blood could be used for
immunological studies (Gemou-Engesaeth et al 1997). Childhood asthma, like asthma in
adults, is associated with activation of T cells and elevated expression of eosinophil-active
cytokines. Furthermore, GC therapy results in clinical improvement and in a decrease in T-
cell activation (Gemou-Engesaeth et al 1997). The few studies on the role of lymphocytes in
smoking-induced airflow limitation in COPD have shown a tissue predominance of CD8+
over CD4+ T cells (O´Shaughnessy et al 1997), and a parallel increase in CD8+ lymphocytes
in peripheral blood (De Jong et al 1997). Furthermore, the presence of bronchial wall
macrophages is evident (O´Shaughnessy et al 1997). These data support the view that the
pattern of inflammatory cells in COPD is different from that in asthma. In COPD, there is
also eosinophil migration towards the airways, but the phenomenon is more pronounced in
asthma (Lacoste et al 1993). There have been no studies on the role of lymphocytes in the
pathogenesis of lung function abnormalities in children born very preterm. 
2.4. Exogenous surfactant therapy in respiratory distress syndrome
2.4.1. Surfactant trials
Surfactant substitution has become an established treatment for neonatal RDS (Soll et al
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1992). Since the pioneering efforts of Robillard et al (1964), Chu et al (1967) and Fujiwara et
al (1980), numerous randomized, controlled trials have demonstrated the immediate
effectiveness of surfactant therapy in the treatment of infants with established RDS (Soll et al
1992). The therapeutic approach has followed two general strategies: administration of
exogenous surfactant within 30 minutes of birth to small preterm infants at high risk of RDS
("prophylactic") and administration of surfactant a few hours after birth to neonates with RDS
in respiratory failure ("rescue"). In randomized clinical trials, synthetic, natural and modified
natural surfactants were used. Surfactant administration at birth or in established respiratory
failure decreases the severity of RDS, the frequency of air leaks (pneumothorax and
pulmonary interstitial emphysema) and neonatal mortality (Soll et al 1992, Jobe et al 1993,
Horbar et al 1993, Schwartz et al 1994). These benefits outweigh the small increase in
pulmonary haemorrhage associated with surfactant supplementation (Raju and Langenberg
1993). In spite of the use of surfactant preparations, CLD continues to develop in a significant
number of preterm infants. Many observers now accept that surfactant does not reduce the
overall incidence of CLD, in part because increases in the overall survival rate create a larger
population at risk of long-term complications (Hudak et al 1992, Jobe et al 1993). However,
the incidence of survival without CLD is significantly increased (Pramanik et al 1993), and in
rescue trials with synthetic surfactant, the absolute incidence of CLD appeared to be
significantly reduced (Corbet et al 1993, Jobe et al 1993). According to many studies,
surfactant given at birth or very early in respiratory failure is associated with a better outcome
than surfactant given later after birth (Kendig et al 1991, The OSIRIS collaborative Group
1992, Kattwinkel et al 1993, Halliday 1995, Cooke 1995, Egberts et al 1997). 
2.4.2. Effect on pulmonary outcome
Administration of surfactant to preterm infants with RDS increases the surface activity at the
air-liquid interface, causing an immediate and dramatic improvement in oxygenation and in
most cases reducing the need for ventilatory support (Soll et al 1992). This can be directly
attributed to stabilization of alveoli and decreased elastic recoil, allowing for better
maintenance of functional residual capacity (Goldsmith et al 1991). Surfactant therapy
improves respiratory compliance and lessens the effort of breathing during the first week of
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life (Couser et al 1990, Morley and Greenough 1991, Bhutani et al 1992). After surfactant
supplementation, the dynamic respiratory compliance of ventilated preterm infants either
improved after a delay of up to 24 hours (Couser et al 1990, Morley and Greenough 1991,
Bhutani et al 1992, Kelly et al 1993) or showed no detectable change (Davis et al 1988).
These modest changes in dynamic compliance may be due in part to distension of the lung
and an increase in FRC following surfactant therapy (Milner 1993). The improvement in
pulmonary function may be short-lived (Davis et al 1988, Couser et al 1990, Morley and
Greenough 1991, Bhutani et al 1992, Goldman et al 1992) and no longer detectable at 28 days
of age (Goldman et al 1992). The improved pulmonary outcome of the surfactant recipients
may have been due to the immediate improvement in lung function, resulting in shorter
exposure to high levels of inspired oxygen and to high ventilatory pressures. Additionally,
surfactant may protect against development of epithelial lesions of the airways during
artificial ventilation (Robertson 1992) and may ameliorate hyperoxic lung injury (Fracica et al
1994). Both barotrauma and hyperoxia cause significant injury to the lungs and airways
(Jackson et al 1990). 
The long-term effects of surfactant therapy on lung function vary, perhaps because of
differences in the techniques used for measuring lung function, differences in the patients
studied or differences in treatment practice, including type and dosage of surfactant. Yuksel et
al (1993) and Abbasi et al (1993) found evidence that synthetic surfactant improved lung
function compared with a placebo group at follow-up after 7-12 months of age. Abbasi et al
(1993) found that infants treated with Exosurf had lower Raw and higher forced expiratory
flow, indicating that there was less injury to the conducting airways with surfactant treatment.
In contrast, the results of Walti et al (1992) and Couser et al (1993) suggest that exogenous
porcine (Walti et al 1992) or bovine (Couser et al 1993) surfactant therapy had no effect on
pulmonary function at 1 to 2.5 years of age in infants surviving RDS. Preliminary data with
controversial results are also available on the long-term pulmonary outcome of surfactant
treatment in children at school age (Kramer et al 1995, Berner et al 1996). 
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2.5. Postnatal glucocorticoid therapy in children born preterm
2.5.1. Controlled trials with dexamethasone
The incidence of CLD in infants born very preterm remains distressingly high in spite of the
reduction in acute morbidity and mortality resulting from the recent introduction of surfactant
treatment for RDS (Soll al 1992). A number of clinical trials have shown that dexamethasone
is effective in shortening the time of extubation and the length of time the patient remained
on mechanical ventilation in ameliorating established CLD (Mammel et al 1983, Avery et al
1985, Harkavy et al 1989, Cummings et al 1989, Kazzi et al 1990, The Collaborative
Dexamethasone Trial Group 1991, Kari et al 1993, Kothadia et al 1999). Dexamethasone also
improves lung mechanics, increasing static CL (Yoder et al 1991, Brundage et al 1992) and
reducing Raw (Brundage et al 1992). The mechanism involved in the improvement of
pulmonary function in CLD is currently poorly understood. The mechanics of action of
dexamethasone might be suppression of lung inflammation (Yoder et al 1991, Watts et al
1992). Others have suggested suppression of lung collagen synthesis (Co et al 1993) or
reduced protein leakage resulting in decreased surfactant inhibition (Kari et al 1994). Low
plasma cortisol values have been documented during the first few days of life in VLBW
infants who subsequently experienced CLD (Watterberg al 1994b) indicating GC therapy. In
contrast, Ballard et al (1996) found no difference in cortisol levels between infants who went
on to develop CLD and those who did not.
Cellular and biochemical studies have shown inflammatory changes in the lungs of ventilated
infants as early as the first few days of life (Merritt et al 1981, Odgen et al 1984, Pierce et al
1995) and dexamethasone has been shown to reduce this inflammation (Yoder et al 1991,
Gronec et al 1993). Thus it has been postulated that steroid treatment administered shortly
after birth may prevent the inflammatory insult to the lung and thereby reduce the likelihood
of CLD (Yeh et al 1990). Previous reports of the use of early postnatal dexamethasone
treatment have provided mixed results. There is evidence to support its role in reducing the
incidence of CLD when treatment is begun during the first week of life (Yeh et al 1990,
Brozanski et al 1995, Durand et al 1995, Rastogi et al 1996, Yeh et al 1997, Lin et al 1999,
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Garland et al 1999). Some recent studies have shown that dexamethasone given to preterm
infants with RDS did not reduce the incidence of CLD and/or death (Sanders et al 1994,
Shinwell et al 1996, Subhedar et al 1997, Tapia et al 1998). Comparisons of the results of
controlled trials on postnatal dexamethasone given during the first few days of life to preterm
infants with RDS are difficult to make because of substantial differences in study design. The
duration and the time of starting treatment, study population selection, simultaneous
surfactant therapy and additional steroid therapy may all affect the result. In addition, the
definition of CLD differs between studies. However, a recent meta-analysis of systemic GC
therapy within the first 2 weeks of life in infants born preterm concluded that this therapy
significantly reduced the risk of CLD. When started between 7 and 14 days of age, there was
also a significant reduction in mortality (Bhuta and Ohlsson 1998).  
The short-term side effects of dexamethasone include hyperglycaemia (Harkavy et al 1989,
Kazzi et al 1990, Collaborative Dexamethasone Trial Group 1991, Bhuta and Ohlsson 1998,
Papile et al 1998), hypertension (Avery et al 1985, Cummings et al 1989, Collaborative
Dexamethasone Trial Group 1991, Bloomfield et al 1998, Bhuta and Ohlsson 1998, Papile et
al 1998), neutrophilia and infection (Yeh et al 1997, Papile et al 1998), diminished weight
gain (Harkavy et al 1989, Yeh et al 1990, Gibson et al 1993, Shrivastava et al 1998, Bhuta
and Ohlsson 1998, Papile et al 1998), reduced bone mineral content (Shrivastava et al 1998),
myocardial hypertrophy (Bensky et al 1996, Bloomfield et al 1998), gastrointestinal
bleeding/perforation (Ng et al 1991), adrenal suppression (Wilson et al 1988, Bloomfield et al
1998) and diminished head growth (Papile et al 1998). Despite the wide use of postnatal
dexamethasone in the treatment of CLD, the long-term effects of dexamethasone therapy
have not been well studied, although concern has been emphasized by various investigators
(Kazzi et al 1990, Frank 1991, Jones et al 1995, Yeh et al 1997). In a recent study in preterm
born infants a 28-day course of systemic dexamethasone started on day 1 of life has been
associated with a higher incidence of neuromotor dysfunction at 2 years of age (Yeh et al
1998). O´Shea et al 1999 found a higher rate of cerebral palsy among dexamethasone-treated
infants at 1 year of age. In an animal model disturbances in lung growth, myelinization and
neurodevelopment have been observed (Howard et al 1975, Weichsel 1977, Beck et al 1981).
Pulse therapy of dexamethasone in preterm infants at risk for CLD has fewer side effects than
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a long course but may be less effective in preventing CLD (Brozanski et al 1995, Bloomfield
et al 1998).
2.5.2. Trials with inhaled glucocorticoid      
Recently, inhaled GC has been proposed as an alternative treatment for infants born preterm
to minimize the systemic complications that occur with parenteral GC. There have been few
controlled trials of inhaled GC in the treatment of newborns with lung disease. Improvements
were found in oxygen requirements, Raw and dynamic CL and time to extubation in
comparison with controls without GC side effects (Pappagallo et al 1991, LaForce and
Brudno 1993, Pokriefka et al 1993, Arnon et al 1996, Fok et al 1999). In a recent study, 253
infants born before 33 weeks requiring ventilation therapy at 3 to 14 days of age were treated
with inhaled beclomethasone or placebo for 4 weeks. In this study, early beclomethasone
therapy did not prevent CLD but was associated with lower rates of use of systemic GC
therapy and mechanical ventilation (Cole et al 1999). Studies of inhaled GC in infants born
preterm have shown promising results with minimal side effects. However, there are
limitations associated with the route of administration and a delayed effect. With systemic
steroids, extubation can be performed as early as 48 hours; in contrast, with inhaled steroid,
the improvement in pulmonary function is only visible after 2 weeks (LaForce and Brudno
1993). Early use of inhaled steroids does not prevent CLD (Cole et al 1999), which is
achieved by the systemic route. The recent study by Groneck et al (1999) in which they
compared the effects of 1500 µg/day of inhaled beclomethasone and systemic dexamethasone
on clinical variables and lung inflammation support this finding (Gronec et al 1999). It is also
important to determine the amount of aerolized drug delivered to intubated babies before
clinical studies when using inhaled GC in the treatment of infants born preterm (Pelkonen et
al 1997).  
Very few data are available on inhaled GC treatment in older infants and children born
preterm. Konig et al (1992) have described the use of nebulized flunisolide in older infants
with CLD. In infants with steroid-dependent CLD between 7 and 18 months of age, the use of
systemic GC has been reduced during inhalation therapy with beclomethasone dipropionate
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(Cloutier et al 1993). Yuksel and Greenough (1992) demonstrated a reduction in symptom
score and an increase in FRC produced by using beclomethasone dipropionate for 6 weeks in
infants born preterm who continued to have respiratory symptoms at the age of 10.5 months
despite bronchodilator therapy. However, Chan and Silverman (1993) selected 15
schoolchildren born preterm, aged 8.2 years, with respiratory symptoms and BHR for
treatment with inhaled beclomethasone dipropionate in a dose of 0.4 mg daily or placebo in a
crossover design for 4 weeks, and found no significant differences in respiratory symptoms,
basic lung function or the response to histamine between these treatments. The authors
suggested that the increased bronchial responsiveness in survivors of preterm birth at school
age was not caused by bronchial inflammation, but was due to abnormal pulmonary develop-
ment caused by preterm birth and neonatal intensive care. These result contrast markedly with
the beneficial effects of corticosteroids on CLD in early infancy. 
2.6. Asthma and children born preterm 
Family history of asthma and prematurity: The relationship between prematurity and asthma
is controversial. There are several studies on a maternal or a family history of asthma as a risk
factor for prematurity, neonatal respiratory disease and CLD. Mothers of preterm born infants
have been found to have a higher incidence of BHR than term infants and their mothers
(Bertrand et al 1985, Riedel et al 1989, Kelly et al 1995). In contrast, Chan et al (1988)
demonstrated that neither the prevalence of maternal asthma nor a family history of asthma
was increased in infants born preterm. Thus whether there is an  association between maternal
BHR or asthma and premature birth remains controversial (Chan et al 1995). Studies that
examined the relationship between a family history of asthma and neonatal respiratory disease
in prematures were also inconclusive (Chan et al 1989a, von Mutius 1993, Hagan et al 1995).
Giffin et al (1995) found that infants with a family history of atopy tended to be born at an
earlier stage of gestation and had higher Raw at 1 year of age. Hagan et al (1995) suggested
that prematurity itself is not associated with a family history of asthma, although in infants
with CLD a family history of asthma may increase the risk of severe CLD. Nickerson and
Taussig (1980) found that a history of physician-diagnosed asthma was more frequent among
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relatives of infants with CLD than among those of infants without CLD. However, other
subsequent studies have not confirmed their finding (Chan et al 1989a, de Winter et al 1995,
Hagan et al 1995). In most studies, no increase in the incidence of atopy was found among
preterm born schoolchildren (Riedel et al 1987, Chan et al 1989a, Northway et al 1990). 
On the other hand, preterm birth is considered to be a risk factor for asthma (Seidman et al
1991). In their large population study, Seidman et al (1995) found that infants with birth
weights of < 2500 g (n=1004) had a significantly increased risk of developing asthma by 17
years of age compared with the reference group with birth weights of 3000-3499 g (n=8369).
Such an association had been suggested previously (Noble-Jamieson et al 1982). 
Asthma and CLD: Most of the earlier studies extending to school age had shown that small
groups of preterm born children with or without CLD had reduced lung function (see section
2). Bronchial obstruction, bronchial lability and BHR, the characteristic features of asthma
(Ryan et al 1982), are common findings, regardless of CLD, although more pronouced in
children with CLD. According to many studies, about half the preterm born schoolchildren
with a history of CLD have a significant bronchodilator response (see section 2.2). In a recent
study, Gross et al (1998) observed that half the children with a history of CLD had a
bronchodilator response at 7 years. Additionally, they found that this bronchodilator response
was not associated with a family history of asthma or with exposure to smoking. Lower
respiratory tract symptoms such as cough and wheezing, i.e. asthma-like symptoms, are
common in preterm born children, particularly in the early years of life (Ford et al 1986,
Myers et al 1986, Lucas et al 1990, Greenough et al 1990b, Elder et al 1996). Although the
prevalence of cough and wheezing seems to decrease after the first few years of life, some
preterm born children have respiratory symptoms later in life, as well (Smyth et al 1981,
Chan et al 1989b, Rona et al 1993). Elder et al (1996) found that the incidence of wheezing
treated with bronchodilators was 14.5% in very preterm infants (n=560) and 3% in a cohort of
term newborns (n=657) during the first year of life. Significant risk factors for recurrent
wheezing were a parental history of asthma, siblings at home, and maternal smoking, with the
addition of immaturity and neonatal lung injury. Low birth weight for gestation had no effect
(Elder et al 1996). On the other hand,
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it is known that a number of children who wheeze during infancy will develop asthma later in
childhood (Martinez et al 1995). 
Follow-up studies have shown that, in general, children born preterm have in later childhood
a greater than expected incidence of BHR (Chan et al 1988), unrelated to neonatal respiratory
events (Chan et al 1989a, Galdes-Sebaldt et al 1989, MacLusky et al 1986, Cano and Payo
1997), but related to prematurity (Chan et al 1988, Galdes-Sebaldt et al 1989). It has been
suggested that airway inflammation in children born preterm is not a mechanism of BHR
similar to asthma (Chan et al 1993). A significant relationship has been found between the
presence of BHR and the duration of mechanical ventilation (Riedel et al 1987, Ahrens et al
1988). Increased prevalence of BHR was also found in young adults with a history of CLD
(Northway et al 1990). A significant relationship between BHR and a personal history of
wheezing has been found in schoolchildren born preterm (Chan et al 1989a). In children born
preterm, BHR has been found to be significantly associated with reduced baseline lung
function (Chan et al 1989a, Koumbourlis et al 1996). 
2.7. Peak expiratory flow variability in asthma
 
The physiological hallmark of asthma is variable bronchial obstruction. All lung function
studies of preterm born schoolchildren have been done only in the clinic. Monitoring
pulmonary function throughout successive days in preterm born schoolchildren, as in 
asthma diagnosis and treatment, might provide information about bronchial lability that
would probably missed with a single measurement obtained in the clinic. Peak flow meters
have been available for this purpose. In adults, home recording of peak expiratory flow (PEF)
is considered to be a useful aid in making the diagnosis, assessing the severity, and
monitoring the treatment of asthma (Kerstjens et al 1994, Sears et al 1997). In children with
asthma, diurnal variation in PEF correlates significantly with asthma symptoms and BHR
(Gern et al 1994, Brand et al 1997). Although diurnal variation in PEF is considered useful in
the diagnosis and treatment of asthma and also in large epidemiological studies in children
(Timonen et al 1997), many basic questions concerning the validity of monitoring pulmonary
function at home are still unanswered. Conventional recordings of PEF in asthma performed
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with hand-held mini PEF meters, as compared with devices capable of electronic storage,
may overestimate the number of recordings, containing a large number of retrospective and
even invented data (Redline et al 1996, Verschelden et al 1996, Chowienczyk et al 1994,
Quirce et al 1995). Compliance in performing spirometry may have decreased during long-
term recordings. In both children and adults, studies comparing simple PEF meters and
devices capable of electronic storage have shown that missing data increased significantly
after 2 weeks of monitoring (Redline et al 1996, Verschelden et al 1996). Also, preliminary
studies of the quality of home spirometry in children have shown a significant decrease in
compliance after the first month of recording, without any significant change in technical
ability to perform the spirometry (Wensley et al 1997). The breathing manoeuvre is strenuous
and requires considerable effort, so co-operation may wane over time and submaximal efforts
create falsely low PEF readings (Enright et al 1994).  
For expiratory flow rates, normal circadian rhythms occur in the absence of external stimuli,
with an afternoon maximum and an early morning minimum when plasma histamine is at its
maximum and plasma cyclic adenosine monophosphate and epinephrine are at their minimum
(Lebowitz 1991). This pattern is exaggerated in asthmatics and is a good indicator of
bronchial lability. The presence of increased bronchial obstruction, reflected by reduced PEF
in asthmatic patients during the early morning hours, is called the morning dip (Engricht et al
1994). The diurnal variation percentage or lability percentage is calculated for each day: the
maximum PEF (usually noon or evening) is subtracted from the minimum PEF (morning or
night-time) to obtain the amplitude (max-min), which is then divided by the mean value for
the day and expressed as a percentage: % lability = (max-min)/mean x 100. A diurnal
variation of 20% or more was a good indicator of asthma (Hetzel et al 1980). Enright et al
(1994) recommended the upper limits of normal PEF lability in healthy non-asthmatic
individuals, as determined by 95th percentiles, 31% in children 6 to 14 yr of age and 19% for
adults.
There is no agreement on the best way to analyse the pattern of PEF changes. A commonly
used method of expressing diurnal changes is to divide the difference between morning and
evening values by their mean, averaged over a period of time (amplitude % mean). In order
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not to lose isolated important drops in PEF, a method known as low percentage best, which is
the lowest PEF as a percentage of the highest PEF occurring over a period of time, is also
used. It is suggested that PEF variation as low % best is easy to perform and clinically
relevant, especially in children (Brand et al 1997).
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3. AIMS OF THE STUDY
1. To investigate the long-term pulmonary outcome, especially bronchial lability, in 
schoolchildren born very preterm with and without a history of CLD.
2. To assess whether neonatal surfactant therapy has had an effect on long-term
pulmonary outcome in schoolchildren born very preterm.
3. To evaluate whether the abnormal lung function in schoolchildren born very preterm
has any immunological features. 
4. To evaluate the reproducibility of home monitoring of pulmonary function in children
and the usefulness of this method for determining bronchial lability in children. 
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4. SUBJECT AND METHODS
4.1. Study populations
Whole study population
The whole study population of 63 schoolchildren born very preterm (birth weight <1500 g
and/or gestational age <30 wk) were part of a group of infants treated at the neonatal
intensive care unit of the Children´s Hospital, University of Helsinki, Finland, between
1980 and 1987. Neonatal data were collected from the hospital records (Table 1). Eighteen
(29%) of these children had a history of CLD (Shennan et al 1988). The children were
subdivided into two groups according to growth status at birth: appropriately grown (AGA)
and with intrauterine growth retardation (IUGR). For that purpose, birthweights and heights
were transformed to gestational age-specific SD units by using fetal growth charts for Finnish
children for girls and boys (Pihkala et al 1989). AGA was considered to be present when birth
weights ranged from -2 to + 2 units. IUGR was diagnosed when the gender- and gestational
age-specific birth weight was < -2 SD units. Eleven of the 63 children (11%) were IUGR. A
group of 25 healthy, local schoolchildren of the same age, all of whom were born at term,
were recruited as a control group. In the methodological part of the study 110 children, all
born at term, with newly diagnosed asthma, were selected as our series for evaluating the
reproducibility of home spirometry.
Study populations in different publications
Study I was a cross-sectional study assessing lung function at school age in CLD and non-
CLD groups. In study I the patients were part of a group of VLBW infants (<1250 g) treated
at the neonatal intensive care unit of the Children´s Hospital, University of Helsinki, Finland,
between 1980-1985. Among the total of 168 survivors, 70 children (42%) had required
oxygen therapy for more than 28 days, and 22 children (13%) were still oxygen-dependent at
the age of 36 postconceptional weeks, which was used as the criterion of CLD (Shennan et al
1990). Of the 22 children with histories of CLD, 12 were traced and were able to participate
in our study. Their gestational ages at birth and the duration of oxygen therapy did not differ
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significantly from those of the remaining CLD children who were not examined (median
gestational age at birth 27.0 vs 26.5, median duration of oxygen therapy 80.5 vs 78.5 days).
Twenty children without CLD but comparable in birth weight and gestational age were also
included; 17 of them completed the study (Table 2). A group of 22 healthy, local
schoolchildren of the same age, all of whom were born at term, were recruited as a control
group for spirometry. Lung function of seven control children was recorded at home.
Table 1.  Neonatal data of 63 schoolchildren born very preterm  
______________________________________________________________________
Characteristics CLD group Non-CLD group p
N = 18 N = 45 values
______________________________________________________________________
Birth weight g 940 (595-1200) 1100 (670-1730) 0.001
SD -0.60 (-4.1-2.40) -0.20 (-4.9-1.9) 0.43
Birth height, cm 35.0 (30.0-37.5) 36.0 (30.0-41.0) 0.008
SD -1.25 (-5.8-4.1) -0.30 (-6.70-3.30) 0.83
Gestational age,  wk 26.8 (24.1-30.1) 27.9 (24.6-35.0) 0.03
Apgar score 1 min 3.0 (0-8) 5.0 (1-10) 0.05
5 min 6.5 (1-8) 7.0 (2-10) 0.05  
IMV, days 53 (6-165) 5 (0-58) < 0.0001
FiO2 > 0.21, days 74 (43-512) 11 (1-65) < 0.0001
FiO2 > 0.4, days 25 (2-257) 1 (0-11) < 0.0001
Postconceptional age when 
O2 discontinued. wk 39 (36.1-98.0) 31 (27.5-35.6) < 0.0001
Boys 9 (50%) 26 (58%) 0.32
RDS 17 (94%) 30 (67%) 0.02
PDA 13 (72%) 16 (36%) 0.008
Air leak 2 (11%) 1 (2%) 0.13
Sepsis 3 (17%) 4 (9%) 0.37
Tracheal/bronchial stenosis 5 (28%) 1 (2%) 0.002
______________________________________________________________________
IMV=intermittent mandatory ventilation, FiO2=fraction of inspired oxygen
Values are expressed as medians (range) or as numbers (%) in the given category
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Table 2. Neonatal data of children participating in study I  
__________________________________________________________________________________________________
Characteristics CLD group Non-CLD group p
N = 12 N = 17 values
__________________________________________________________________________________________________
Boys/girls 4/8 7/10 NS
Birth weight, g 955 (620-1200) 980 (690-1240) NS
Gestational age, wk 27 (24-30) 28 (25-35) NS
IMV, days 53 (16-165) 9 (0-58) < 0.001
FiO2 > 0.21, days 81 (50-135) 35 (1-65) < 0.0001
FiO2 > 0.4, days 26 (5-87) 1 (0-6) < 0.0001
Postconceptional age when
O2 discontinued, wk 39 (36-44) 34 (29-35) < 0.0001
RDS * 10 (83%) 9 (53%) < 0.05
PDA ** 8 (67%) 7 (41%)  NS
Air leak 1 (8%) 0 (0%) NS
Sepsis 2 (17%) 2 (12%) NS
Tracheal/bronchial stenosis 4 (33%)  1 (6%)             NS
__________________________________________________________________________________________________
IMV=intermittent mandatory ventilation, FiO2=fraction of inspired oxygen
Values expressed as medians (range) or as numbers (%) in given category
* Typical chest X-ray changes and requirement of supplementary oxygen for at least 2 days
**Requirement of pharmacological or surgical closure
Study II was a cross-sectional study evaluating the effect of surfactant therapy on lung
function at school age. The series examined in study II consisted of patients who were born
before 30 weeks of gestation and had participated in the following three randomized bicenter
(University of California, San Diego, CA., and University of Helsinki, Finland) trials of
human surfactant therapy in the Children´s Hospital, University of Helsinki, Finland, between
1983-1987 (Hallman et al 1985 (study 1), Merritt et al 1986 (study 2),
Merritt et al 1991 (study 3)). In study 1, human surfactant was given to infants with
established neonatal RDS (rescue therapy) after clinical, radiographic, and biochemical
documentation of surfactant deficiency (Hallman et al 1985). In study 2, human surfactant
was given within 10 minutes of birth to infants at high risk of neonatal RDS (Merritt et al
1986). Study 3 was a placebo-controlled comparison between prophylactic and rescue therapy
of human surfactant given to small preterm infants with lung immaturity (Merritt et al 1991).
Infants who were randomized to the placebo group received an injection of air from shielded
syringes in an identical fashion to the surfactant-treated infants.       
Of the Finnish children who participated in the trials during 1983-1987 in Helsinki, 65
survived the first year of life. The addresses of seven (11%) could not be traced, nine (14%)
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refused to participate, and nine (14%) children were unable to perform the tests because of
neurological limitations. Forty children completed the tests of pulmonary function at 7-12
years of age. Of them, 17 were originally included in the prophylactic group, 14 in the rescue
group, and 9 in the placebo group. No statistically significant differences in gestational age,
birth weight, duration of oxygen or ventilator treatment were observed between these three
groups or between the three studies. The duration of high oxygen treatment tended to be
shorter in the prophylactic group than in other groups (p=0.04). Eleven (28%) children
dependent on supplementary oxygen at the age of 36 postconceptional weeks, were diagnosed
as having CLD (Shennan et al 1988) (Table 3). The infants who did not participate in the
follow-up study had similar incidence of CLD. Prenatal glucocorticoids were not used. Only
three children had received glucocorticoid during treatment in the neonatal intensive care
unit. As a reference group, we recruited 20 healthy, local school children of the same ages, all
of whom were born at term. None of them had respiratory symptoms at the time of the study. 
Table 3. Neonatal data of children participating in study II
____________________________________________________________________________________________________________
Characteristics Prophylactic Rescue Placebo
group group group
N = 17 N = 14 N = 9
____________________________________________________________________________________________________________
Boys/girls 14/3 8/6 4/5
Birth weight, g 1119 (258) 1025 (316) 1097 (282)
Gestational age, wk 27.4 (1.6) 27.1 (1.6) 27.4 (1.4)  
IMV, days 7 (1-85) 8 (1-165) 14 (1-80)
FiO2 > 0.21, days 10 (3-131) 49.5 (2-512) 43 (1-75)
FiO2 > 0.4, days 1 (0-87)* 3 (0-257) 5 (0-45)
Postconceptional age when 
O2 discontinued, wk 29.9 (27.7-43) 33.8 (27.5-98) 34.0 (28-46.4)
Tracheal/bronchial stenosis 1 (6%) 2 (14%) 0 (0%)
CLD ** 2 (12%) 5 (36%) 4 (44%)
__________________________________________________________________________
Values are expressed as means (SD), as medians (range) or as numbers (%) in a given category.  *  
Significant difference compared with the other groups (p=0.04).
**  Requirement of supplementary O2 at the age of 36 postconceptional weeks.
Study III was an immunological evaluation at school age in children born very preterm. This
study was the follow-up study to investigate whether there had been an immunological basis
for the lung function abnormalities in schoolchildren born very preterm, 34 (24 males and 10
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females) of these 40 children in study II participated, at a median (range) age of 8.8 (7.4-11.7)
years. The median (range) birth weight of these children was 1090 (595-1730) g and the
median gestational age 27.4 (24.9-29.9) weeks. The median (range) duration of mechanical
ventilation and duration of supplementary oxygen treatment during the neonatal period were
5.5 (1-129) and 10 (1-512) days, respectively. 
A group of 14 healthy schoolchildren of the same age (median (range) age 9.1 (5.8-13) years),
born at term, was recruited as a control group. These children were attending school at the
time of the study and had neither respiratory symptoms nor symptoms of atopy.
Study IV was a longitudinal study evaluating the effect of inhaled budesonide on lung
function of schoolchildren born very preterm. Twenty-one of all 63 children (studies I and II)
born very preterm without a previous diagnosis of asthma, but with bronchial obstruction,
increased responsiveness to a beta2 agonist and/or abnormal diurnal PEF variation (i.e. A
20%) were selected for the budesonide trial, which was completed by 18 children. The
median (range) birth weight of these children was 1054 (640-1600) g and the median (range)
gestational age 28 (24-35) weeks. The median (range) duration of mechanical ventilation and
duration of supplementary oxygen treatment during the neonatal period were 6 (0-80) and 27
(1-131) days, respectively. Six children were dependent on supplementary oxygen at the age
of 36 postconceptional weeks, which was used as the criterion of CLD (Shennan et al 1988).
Nine had been treated with exogenous surfactant. 
  
A group of 11 healthy local schoolchildren of the same age (mean (SD) age 10.3 (2.4) years),
all born at term, were recruited as a control group for home monitoring. These children were
attending school and had no respiratory symptoms at the time of the study. 
Study V was a methodological study assessing the reproducibility of home monitoring in
children. In study V, 110 outpatients, at a mean (SD) age of 7.4 (1.6) years, of whom 62%
were male, with newly diagnosed asthma, were selected as our series for evaluating the
reproducibility of home spirometry. The children participated in a study of early
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pharmacological intervention in childhood asthma. Inclusion criteria were asthma symptoms,
abnormal diurnal variation of PEF (A20%) in the last 3 months preceding the first visit to the
clinic, recorded daily at home in paper diaries; and/or a A 15% change as measured by PEF or
FEV1 or A 36% by FEF50 proved either by a bronchodilator test or in an exercise test in the
clinic or during home monitoring. 
Before the studies, informed consent was obtained from all parents and children over 7 years
old. All studies were approved by the Ethics Committee of the Department of Allergic
Diseases at Helsinki University Central Hospital.
4.2. Study designs
Studies I-IV
For the lung function studies, all 63 schoolchildren born very preterm (studies I-IV) made two
visits to the Outpatient Department of Allergic Diseases, in the University of Helsinki Central
Hospital. These children underwent lung function testing, using an identical protocol and
equipment. 
At the first visit, clinical status was studied, and questionnaires focusing on respiratory
symptoms during the preceding year were filled out. Flow-volume spirometry and a
bronchodilator test were performed, and the children were trained to use a home spirometer.
In addition, skin-prick tests were made. After the hospital visit, lung function was monitored
twice daily at home for 4 weeks. The effect of a β2 agonist was measured by spirometry
before and after terbutaline inhalation every morning and evening for the first 2 weeks of
home monitoring, followed by treatment with a placebo for 2 weeks. Parents and children
were blinded to these treatments. 
At the second visit, flow-volume spirometry was performed, and the data of the home
spirometer were downloaded. The spirometric values measured at the first visit were used to
evaluate basic lung function. The values at the second visit were used to compare spirometry
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at home and in the clinic. In study I a histamine challenge test were performed and in study III
a blood sample was taken for determination of serum ECP and MPO, and for measurement of
lymphocyte subsets at the second visit. 
Selected 18 children (study IV) were treated with inhaled budesonide (Pulmicort TurbuhalerR,
0.2 mg/dose, Astra Draco AB, Lund, Sweden) in initially high (0.8 mg/m2/day for 1 month)
and subsequently lower doses (0.4 mg/m2/day for 3 months) divided into morning and
evening doses. Monitoring of spirometric values at home continued twice daily for 4 weeks
during the first month of budesonide treatment. After that (at the third visit to the clinic),
flow-volume spirometry was performed and the home spirometer was downloaded. During
the last 4 weeks of the GC treatment period, home recording of spirometric values was per-
formed twice daily. At the fourth visit to the clinic, body height and weight were measured,
flow volume spirometry was performed, and the home spirometer was downloaded. The
mean FVC, FEV1 and PEF values during the second week of the β2 agonist, a placebo and GC
treatment were calculated. The numbers of abnormal diurnal PEF variations were recorded
and compared between the following periods: 2 weeks of terbutaline treatment, 2 weeks of
placebo treatment, and 2 weeks of GC treatment, respectively. 
Study V
In study V, the 110 children born at term with newly diagnosed asthma made two visits to the
Outpatient Department of Allergic Diseases, Helsinki University Central Hospital, for the
lung function studies. Home spirometry was performed during the run-in phase of a study of
early pharmacological intervention in childhood asthma. Each child underwent a lung
function recording. The protocol and equipment used were identical throughout the study. At
the first visit to the clinic, a physical examination was performed and body height and weight
were measured. The children were instructed step by step in the use of the home spirometer.
Lung function was then monitored twice daily at home for 24 days (mean) before starting the
anti-inflammatory asthma medication. During the run-in period, the children were allowed to
use an inhaled β2 agonist if needed. Measurements with the spirometer was recorded at home
every morning between 0600 and 1000 hours and every evening between 1800 and 2200
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hours. Flow-volume spirometry was performed at the first and second visits. At the second
visit to the clinic, the data of the home spirometry were downloaded on a computer.
All 25 control children underwent lung function testing, using a protocol and equipment
identical to that used for the study children. Spirometry was done by all the control 
children, a group of 14 children underwent the histamine challenge test and 11 were recruited
as a control group for the home monitoring.  
4.3. Skin prick tests
Skin tests were performed by a trained nurse at the Outpatient Department of Allergic
Diseases, Helsinki University Central Hospital, with the skin-prick technique, using eight
major respiratory allergen extracts. A negative control solution and histamine hydrochloride
(10 mg/ml) as positive control were used. Atopy was defined as at least one wheal  A 3 mm in
diameter as a reaction to an allergen in the absence of a response to the negative control sol-
ution. Familial atopy was defined as physician-diagnosed allergy among first-degree relatives.
Atopy of control children was evaluated by any evidence of specific serum IgE (positive
Phadiatop Combi testR, Pharmacia Diagnostics, Uppsala, Sweden).
4.4. Lung function and the nonspecific bronchial provocation tests 
Flow volume spirometry was done with a pneumotachograph (Spirotrac IIIR, Vitalograph
Ltd., Buckingham, UK). At least three technically correct forced expiratory curves should be
made according to the acceptability criteria of the American Thoracic Society (ATS). The
curve was regarded as reproducible if the largest FVC and FEV1 and second largest FVC and
FEV1 of the acceptable curves did not vary by more than 5% of the reading (expressed as a
percentage of the largest observed FVC and FEV1, regardless of the curve on which it
occurred) (ATS 1995). The curve with the highest sum of FEV1 and FVC values was selected
for statistical analysis. Results of lung-function tests were analysed as  percentages of
predicted values, according to Polgar and Promadhat (Polgar and Promadhat 1971). The
following spirometric parameters were recorded: FVC, FEV1, FEV1/FVC ratio, PEF, FEF50
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and FEF75. Bronchial obstruction was defined as at least two of the following spirometric
values: FEV1<80%, PEF<75% or FEF50<62% (Polgar and Promadhat 1971). 
In the bronchodilator test in the office, flow-volume spirometry was measured before and 15
min after inhalation of terbutaline 0.5 mg from a dry powder inhaler (terbutaline sulfate
0.25mg/dose, Bricanyl TurbuhalerR, Astra Draco AB, Lund, Sweden). During each terbutaline
inspiration, peak inspiratory flow through the dry powder inhaler, Turbuhaler, with a
pneumotachograph (Spirotrac IIIR) was recorded (PIFTBH). The lowest acceptable PIFTBH value
was 30 l/min (Pedersen et al 1990). The changes in FEV1 and PEF values after terbutaline
were expressed as the differences (%) between the values before and after terbutaline inhala-
tion (∆FEV1 and ∆PEF). A positive response to terbutaline was defined as a FEV1 or PEF
increment of A 15% after terbutaline in the clinic or at home (ATS 1991). 
At home, lung function was recorded with a Vitalograph Data Storage Spirometer
(Vitalograph) particularly designed for long-term recording and storage of lung function
parameters. The device consists of a pneumotachograph and a built-in electronic diary. Before
use, the device was calibrated with a standard volume (variation within +/- 1%). After home
recordings, the calibration was rechecked. The difference between these two calibration
values (before and after home monitoring) was calculated. At home, FVC, FEV1 and PEF
values were recorded and the date and time logged at each test session. The child should stand
up during the procedure and use a nose clip. The test was repeated a maximum of five times,
until the results of the two best values met the reproducibility criteria of ATS. If this was not
achieved with five tests, failure was recorded. The spirometer stored the curve with the
largest sum of FEV1 and FVC in the built-in electronic diary. The measurements were made
at least 5 hours after inhalation of a β2 agonist. The compliance of inhalation therapy was
recorded by measuring PIFTBH. During the first 2 weeks of home monitoring, the children
inhaled terbutaline 0.25 mg twice daily. They performed spirometry every morning and even-
ing before and 15 min after terbutaline inhalation, followed by treatment with a placebo for 2
weeks. The data from the home spirometer were analysed after 4 weeks´ monitoring. The
number of PEF increments reaching 15% or more after terbutaline was used for the analysis
(ATS 1991). The diurnal PEF variation of the whole 4 weeks´ recordings was calculated as
the difference between the morning and evening PEF values and expressed as a percentage of
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the greater PEF value. The number of ∆PEF A 20% was used in the analysis. ∆PEF A 20%
has been shown to be a good indicator of bronchial lability (Hetzel et al 1980, Lebowitch et al
1991). The number of positive terbutaline responses and the number of ∆PEF A 20% were
expressed as percentages of all the tests during home monitoring. PEF increments A 15%
after terbutaline at least three times (A 11%, expressed as percentages of all the tests during
home monitoring) during 2 weeks and diurnal PEF variation A 20% at least four times (A
14% of all tests) during 4 weeks were considered abnormal. The mean FEV1, FVC and PEF
values, defined as the means of the morning values during the last week of home monitoring
periods, were calculated. 
In study V the reproducible home measurements were calculated as percentages of all the
spirometric tests registered in order to evaluate the reproducibility of home spirometry. We
also calculated the home spirometry measurements according to looser criteria than those set
by ATS, i.e., accepting levels at which the largest and second largest FVC and FEV1 values
from reproducible spirometric curves at home did not differ by A 10% or A 15% of the
recordings. In order to evaluate the compliance in home monitoring, we calculated the
number of computer-registered spirometric tests and expressed the result as a percentage of
the number of all desired tests during the whole home monitoring period.  
 
In study I the histamine challenge test followed a protocol previously described (Sovijärvi et
al 1993). Airway responsiveness to histamine, expressed as the histamine dose (mg) resulting
in a 15% decrease in FEV1 (PD15 FEV1), was determined using an automatic, inhalation
synchronized, dosimetric jet nebulizer (Spira Elektro 2, Respiratory Care Centre,
Hämeenlinna, Finland). The device incorporates a turbine flow sensor for monitoring tidal
volume and inspiratory flow. With a two-bar driving pressure, the airflow to the nebulizer is
7.5 l/min. The nebulization time is 0.4 s, set to start at 100 ml after the beginnig of
inspiration. During the test, the child is breathing with a tidal volume of 0.3-0.5 litres. The
peak inspiratory flow is not allowed to exceed 0.5 l/s during administration of the aerosol.
One, four, eight and sixteen tidal inspirations of buffered histamine diphosphate in saline
solution with concentrations of 4 and 16 mg/ml are employed using a four-step dosage
scheme. The calculated non-cumulative doses of histamine to the lungs and airways at each
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step are 0.025, 0.1, 0.4, 0.8 and 1.6 mg, respectively. The FEV1 measured with a
pneumotachograph is used to determine the response to histamine. The PD15FEV1 is
determined by manually plotting the dose of histamine against the % fall in FEV1 using a
logarithmic scale for the histamine doses. The PD15FEV1 is obtained by linear interpolation
between the last two points. PD15 FEV1 values A 1.6 mg histamine are considered normal for
adults (Sovijärvi et al 1993). After the last histamine dose, 0.5 mg terbutaline was given.
Terbutaline was inhaled from a metered-dose inhaler with a valved spacer device
(NebuhalerR, Astra Draco AB, Lund, Sweden). If the child had a respiratory infection, the test
was not performed until 2 weeks after the infection had ended. The children were not allowed
to use β2 agonists for at least 12 h before the challenge test. 
4.5. Markers of inflammation
In study III, blood for ECP and MPO was taken in gel tubes (SST, Becton-Dickinson,
England) and allowed to clot at room temperature for 60 (±10) min. Serum was separated by
centrifugation at 1350 x g for 10 min and stored at -20o  C until analysed for ECP (Venge et al
1977) and MPO (Bousquet et al 1991), using a radioimmunoassay (Pharmacia Diagnostics,
Uppsala, Sweden) according to the manufacturer´s instructions. Blood eosinophils were
counted with a haematological analyser (Advia 120, Bayer).
For flow cytometric analysis, peripheral venous blood samples were drawn in heparin.
Thereafter, mononuclear leucocytes were isolated by Ficoll-Paque centrifugation at 400 g for
30 min. Subsequently, a mononuclear blood cell suspension at a cell concentration of 1 x
106/ml in RPMI 1640, with antibiotics, glutamine, and 5% fetal calf serum, was incubated at
40 C for 10 min with monoclonal antibodies against CD3, CD4, CD8, CD19, CD23, CD25
and CD16+56 (which are natural killer (NK) cells) (Beckton Dickinson Immunocytometry
Systems, Mountain View, California) according to the manufacturer´s instructions (Macey
1994). Flow cytometric analysis was then performed, using the same instrument settings in
each analysis. The lymphocytes were finally gated to study the numbers of cell subsets within
the gate. The numbers of cells positive for the surface markers are expressed as percentages
of all the cells within the gate.    
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4.6. Statistical methods
Statistical analyses were performed using the Statgraphics computer program (studies I, II,
IV), the MacIntosh Stat View computer program (study III) and the statistical package
STATISTICA (release 5.0 for Windows) (study V and combined data). Results of lung
function tests were analysed as percentages of predicted values (Polgar and Promadhat 1971).
In study I the significances of the differences between the three study groups were tested
using one-way analysis of variance for normally distributed data. A Kruskal-Wallis non-
parametric test was used if the distribution was not normal or if the variances were not
homogeneous. Fisher´s exact test and the Mann-Whitney test were used for assessing the
significance of differences between the two groups. Spearman´s rank correlation (rs) was used
in analysis for the association between current symptoms and the lung function parameters.
Multiple stepwise regression analysis was used to evaluate the relationship between the
neonatal (independent variable) and current pulmonary function (dependent variable) data.
The following neonatal variables were evaluated: birth weight, duration of oxygen therapy
(FiO2>0.40 and FiO2>0.21), duration of ventilator treatment, postconceptional age when O2
discontinued, and history of tracheal/bronchial stenosis.
In study II the study groups were tested for significant differences using one-way analysis of
variance for normally distributed data. A Kruskal-Wallis non-parametric test was used if the
distribution was not normal or if the variances were not homogeneous. Fisher´s exact test was
used for assessing the significance of differences between the two groups. Multiple regression
analysis was used for evaluating the relationship between the prenatal-neonatal variables and
the pulmonary function data. On the basis of the correlation matrix consisting of 38 neonatal
variables and the lung function parameters, the following two independent variables were
evaluated for association with the spirometric parameters: surfactant treatment (yes/no) and
the duration of intubation. In addition, the following variables were evaluated: duration of O2
therapy of at least 40%, duration of supplemental O2 therapy, and diagnosis of
tracheobronchial stenosis (yes/no) and of CLD. Being associated with CLD and/or fatal
neonatal RDS, the SP-A/DPC ratio, analysed in airway specimens recovered at the age of one
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day, was used as the covariate. Gestational age was included as another covariate in the
regression analysis. 
In study III the data of the children born very preterm and the controls were compared using
the Mann-Whitney test or the Fisher exact test. A Kruskal-Wallis non-parametric test was
used to determine the differences between the three study groups (preterm-born
schoolchildren with and without bronchial obstruction and controls). Spearman´s rank
correlation (rs) was used to evaluate the association between lung function and the results of
the blood tests overall and within the groups. 
In study IV, Spearman´s rank correlation (rs) was used to analyse the correlation between the
neonatal variables and the subsequent lung function parameters and between the different
lung function parameters and the symptoms. Statistical comparisons of longitudinal lung
function measurements during terbutaline, placebo and budesonide treatment were performed
with Friedman´s non-parametric analysis of variance. 
In study V the reproducibility of the home measurements was estimated by calculating the
percentage of home spirometry measurements that met the levels of reproducibility @ 5%
(ATS criteria), <10% and <15%. The children were assigned to three categories according to
age (5-6 years, 7-8 years and 9-10 years), and to height (< 121 cm, 121-135 cm and 136-150
cm). Differences between groups were tested using analysis of variance (ANOVA), and, to
adjust for multiplicity, Fisher`s LSD method was used in pairwise comparisons. The
differences between compliance in performing the spirometric tests and the reproducibility of
the tests during the first and third week at home were analysed by the paired t-test. Regression
analysis was used to evaluate the relationship between age and height and the percentage of
home spirometry measurements that met the ATS criteria. Pearson correlation coefficients
were calculated to study the relationship between age and height versus the percentage of
reproducible home spirometry measurements, using three levels of reproducibility, @ 5 %,
<10 % and <15 % and also between baseline spirometry in the clinic and the percentage of
home spirometry measurements that met the ATS criteria.
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In combined data (Tables 1, 4, 5, 6 and 7) t-test for independent samples was used to compare
the CLD group with the non-CLD group. In a case of skew variables, the Mann-Whitney test
was used. The chi-square test was used to compare binary variables. Analysis of variance was
used to compare more than two groups and, because of non-equal variances, Games-Howell
tests were performed for post hoc multiple comparisons. Kruskal-Wallis and Mann-Whitney
tests for pairwise comparisons were done if the normal distribution assumptions could not be
made. Stepwise regression analysis was performed to identify the best combinations of
neonatal variables to predict the current pulmonary function variables, and correspondingly
stepwise logistic regression analysis was performed to identify the explaining variables in
binary conditions, such as bronchial obstruction. In analysing the association between the
different lung function parameters, Spearman´s rank correlation (rs) was used.
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RESULTS
5.1. Bronchial lability and responsiveness in schoolchildren born very preterm 
(Study I and study II)
Patients
In all 63 children, age, height in SD units, weight, and weight expressed as a percentage of
the mean weight of children of the same sex and height (Sorva et al 1984) did not differ
between the CLD, non-CLD and control groups. Heights as SD in relation to age were signifi-
cantly lower in the CLD children than in the full-term controls (p=0.02) (Table 4). 
History of respiratory symptoms and atopy
A total of 38 children (60%) had had respiratory symptoms during the year prior to the study.
Twenty-six children (41%) had had dyspnoeic symptoms at least once and, in addition, 12
children had suffered from continuous coughing for more than 3 weeks. Ten children (16%)
had asthma diagnosed by a physician. Eight of them were receiving continuous budesonide or
disodium cromoglycate inhalation therapy and one child used a β2 agonist during infections.
The groups did not differ in individual or familial atopy or in parental smoking. Atopy was
found in 28% of patients in the CLD and in 18% in the non-CLD group. The respective
percentages of familial atopy were 44 vs. 36%. The percentages of parental smoking were
high in both groups; 39% in the CLD and 40% in the non-CLD group (Table 5).
Basic lung function 
All 63 children performed a complete set of spirometer tests (three pre- and three post-β2
agonist) in the clinic. Fifteen children (83%) in the CLD group and fourteen (31%) in the
non-CLD group had spirometric values in the clinic indicating bronchial obstruction
(p<0.001) (Table 5). Of these children with obstruction, 18 (62%) reported respiratory
symptoms during the past year. All spirometric values were significantly lower in the preterm
group than in the full-term controls (p@0.01). When the three groups were analysed
separately, all spirometric values except FVC in the non-CLD group were 
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Table 4. Demographic data at entry of 63 schoolchildren born very preterm  
__________________________________________________________________________________
CLD group Non-CLD group Full-term p values
N = 18 N = 45 N = 25 ANOVA
__________________________________________________________________________________
Age, yrs 9.8 (7.7-13.9) 10.2 (7.4-12.8) 10.6 (5.7-13.6) 0.70
Height, cm 130.5 (114.5-150.5) 135.7 (115.2-167.0) 141.3 (115.1-165.1) 0.14
Height, SD units -1.4 (-4.0 to 1.6)* -0.5 (-2.2 to 2.8)** 0 (-3.0 to 1.3) p=0.03
Weight, kg 26.9 (16.5-45.0) 30.8 (19.3-55.0) 33.8 (17.0-67.3) 0.13
Height-related -1.0 (-20 to 17) 0 (-27 to 55.0) 0 (-16 to 54) 0.76
weight (%) 
__________________________________________________________________________________
Values expressed as medians (range)
* p = 0.02 compared with the full-term controls
** p =0.02 compared with the CLD group
Table 5. Respiratory symptoms, atopy, risk factors during the past year and present findings
of bronchial obstruction
________________________________________________________________________
Characteristics CLD group Non-CLD group p 
N=18 N=45 values
________________________________________________________________________
Atopy 5 (28%) 8 (18%) NS
Familial atopy* 8 (44%) 16 (36%) NS
Parental smoking 7 (39%) 18 (40%) NS
Physician-diagnosed asthma 5 (28%) 5 (11%) NS
Respiratory symptoms 12 (67%) 26 (58%) NS
Dyspnoeic symptoms 9 (50%) 17 (38%)
Prolonged cough 3 (17%) 9 (20%)
Bronchial obstruction 15 (83%) 14 (31%) <0.001
Bronchial lability** 8 (47%) 23 (54%) NS
________________________________________________________________________
* Physician-diagnosed allergy among first-degree relatives.
**A significant response in the bronchodilator test and/or abnormal diurnal PEF variation
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significantly lower in both preterm groups than in the full-term controls (Figure 1). All
spirometric values except FEV1/FVC were significantly lower in the CLD than in the non-
CLD group (Figure 1). 
There were no significant differences in lung function between the children without a history
of RDS and CLD (N=15) and those with a history of RDS but not CLD (N=30) when the
groups were analysed separately. However, the children without a history of RDS and CLD
had significantly lower FEV1, PEF, FEF50 and FEF75 values than the healthy controls (Table 6,
Figure 2).
Bronchodilator test and diurnal PEF variation 
In the bronchodilator test in the clinic, one of the study children had a significant response to
terbutaline (∆FEV1A15%) (ATS 1991). Five children had ∆FEV1 A 10% (one non-CLD and
four CLD children). There was no significant difference between the CLD and non-CLD
groups; the median ∆FEV1 was 5.8% (range -5.1-29.1.3%) in the CLD and 2.3% (range -4.1-
14.7%) in the non-CLD group (p=0.08). 
During the 2 weeks´ recording at home, PEF increments A 15% after terbutaline were
observed at least three times (A 11%, expressed as percentages of all the tests during home
monitoring) in 40% of the patients. According to this definition, none of the 11 control
children had a positive bronchodilator test at home. The difference between the preterm group
and the healthy controls were significant (p=0.002) (Figure 3). When the groups were
analysed separately, there were no significant difference between the preterm born groups,
although CLD and non-CLD groups differed significantly from the controls (p@0.01). 
Fourteen children (22%) had diurnal PEF variation A 20% at least four times (A 14% of all
tests) during home monitoring. According to this definition, none of the control children had
abnormal diurnal PEF variation and the difference between the preterm group and the healthy
controls was significant (p=0.006) (Figure 3). When the groups were analysed separately,
there were no significant difference between the preterm born groups, although CLD and non-
CLD groups differed significantly from the controls (p@0.03).
Table 6. Lung function in three groups of schoolchildren born very preterm (according to CLD and RDS) and in full-term controls
__________________________________________________________________________________________________________________________________
A1 A2 A3 B p
Non-RDS RDS values
Non-CLD Non-CLD CLD Full-term AI vs A2 A2 vs A3 A1 vs B
N = 15 N = 30 N = 18 N = 25
__________________________________________________________________________________________________________________
FEV1 84.4 (39.3-103.8) 87.3 (70.2-104.8) 71.4 (40.7-88.9) 94.2 (79.2-117.7) 0.54 <0.0001 0.04
FVC 97.0 (39.2-121.4) 95.5 (76.5-114.6) 84.6 (44.9-98.6) 98.6 (84.0-123.7) 0.99 0.01 0.75
FEV1/FVC 89.3 (72.6-100.4) 91.0 (77.9-109.3) 87.3 (67.2-107.3) 96.9 (85.9-105.4) 0.23 0.34 0.008
PEF 73.8 (38.0-90.3) 76.6 (53.6-100.7) 59.1 (373-86.4) 89.0 (72.5-110.9) 0.48 0.001 0.002
FEF50 75.2 (37.4-102.9) 84.4 (47.5-115.5) 58.1 (29.5-89.5) 108.4 (72.8-153.9) 0.20 0.0002 <0.0001
FEF75 56.9 (217-86.0) 67.4 (35.3-137.4) 45.0 (14.4-82.5) 84.0 (51.6-146.6) 0.13 0.006 0.0003
Diurnal PEF variation ≥ 20%
N = 14 N = 28 N = 17 N= 11
1.00(0-9) 1.00(0-9) 2.00(0-8) 0.00 (0-1) 0.54 0.22 0.07
Bronchodilator test at home
2.50(0-10) 2.00(0-8) 2.00(0-7) 0.00(0-2) 0.31 0.37 0.001
___________________________________________________________________________________________________________________________________
Values are expressed as medians (range).
Lung function tests are expressed as percentages of the predictive values or as numbers in a given category.
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Figure 1. FEV1, FVC and FEV1/FVC (A) and PEF, FEF50 and FEF75 (B) values as percentages
of predicted values of the children in the different study groups (open circles: history of tra-
cheal/bronchial stenosis). Medians are indicated by horizontal lines. Significant differences
are indicated in the figure when the three groups are analysed separately.
54
Figure 2. Schematic presentation of spirometric values measured in the clinic in the
schoolchildren born very preterm and grouped according to the neonatal history. Flow-
volume curves are presented above and time-volume curves below. A1; children born very
preterm without a history of RDS and CLD (N=15). A2; children born very preterm with a
history of RDS but without a history of CLD (N=30). A3; children born very preterm with a
history of CLD (N=18). B; full-term controls (N=25).
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Figure 3. The number of PEF measurements with an increment A 15% after terbutaline and 
diurnal PEF variations A 20% during home monitoring expressed as percentages of all the
tests during home monitoring (open circles: history of tracheal/bronchial stenosis). Medians
are expressed as horizontal lines. Significant differences between the preterm group and the
healthy controls are expressed in the figure. CLD: schoolchildren born very preterm with a
history of CLD. Non-CLD: schoolchildren born very preterm without a history of CLD.
Controls: full-term healthy controls.
 A significant response in the bronchodilator test and/or abnormal diurnal PEF variation were
observed in 30 of the 63 children tested (48%) and in 19 (66%) of the 29 children with
verified obstruction. In the children with bronchial lability (a significant response in the
bronchodilator test and/or abnormal diurnal PEF variation) only the PEF values were
significantly lower than in children without bronchial lability (p=0.02). Significantly more of
the preterm born children without a history of RDS and CLD had bronchial lability than of
the healthy controls (Table 6). 
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Bronchial responsiveness
Median histamine PD15FEV1 was significantly lower in the CLD group than in the non-CLD
group; 0.8 (range 0.06 -  >1.6) vs. >1.6 (range 0.44 - >1.6), (p = 0.01) or in the full-term
controls (>1.6, range 0.41- >1.6) (p=0.02). No significant differences were observed between
the non-CLD group and the full-term controls (median PD15FEV1 >1.6 vs. >1.6 mg) (Figure
4).
Figure 4. The results of histamine challenge tests as PD15FEV1 in the children in the different study
groups (open circles: history of tracheal/bronchial stenosis). Medians are indicated by horizontal
lines. Significant difference between the CLD group and the non-CLD group is indicated in the
figure. CLD: schoolchildren born very preterm with a history of CLD. Non-CLD: schoolchildren
born very preterm without a history of CLD. Controls: full-term healthy controls.
Home monitoring was not acceptable in three children because of technical faults in the
device and one child with the history of tracheal stenosis had severe symptoms and was
unable to perform the histamine challenge test or carry out home monitoring. With the other
children the percentages of acceptable individual measurements at home was high: 89%
(range 54-99%). 
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Association of neonatal variables and current respiratory symptoms with subsequent lung
function (all study children)
The duration of ventilator treatment was significantly associated with FVC, PEF and
PD15FEV1 values and the duration of oxygen therapy with FEV1 and FEF75 values. A history
of tracheal/bronchial stenosis was associated with FEF50. Parental smoking was associated
with FEV1 and PEF values (Table 7). Neither gestational age nor birthweight was associated
with the spirometric data or with the bronchial responsiveness.  
Table 7. Association between neonatal variables and subsequent lung function in schoolchildren born
very preterm. Results of stepwise multiple regression analysis and logistic regression analysis:
_______________________________________________________________________________
Dependent lung Independent Regression Standard p R2 values
function variable variable coefficient error values (adjusted)
_______________________________________________________________________________
FVC IMV (days) -0.14 0.07 0.039
Postconceptional age when O2 0.331
discontinued (wk) -0.50 0.24 0.040
 Parental smoking* -6.22 3.44 0.076
FEV1 IMV (days) -0.12 0.06 0.067
Postconceptional age when O2 0.321
discontinued (wk) -0.49 0.22 0.033
Parental smoking* -6.51 3.23 0.049
PEF IMV (days) -0.19 0.05 <0.001
Parental smoking* -9.5 3.4 0.007 0.290
FEF50 FiO2>0.4 (days) -0.08 0.20 0.673
Tracheal/bronchial
stenosis (yes/no)* -20.88 10.2 0.046
Parental smoking* -7.81 5.44 0.157 0.134
Postconceptional age when O2
discontinued (wk) -0.01 0.75 0.992
FEF75 FiO2>0.4 (days) -0.212 0.09 0.024  
Tracheal/bronchial 0.132            
stenosis (yes/no)* -11.24 10.87 0.306
PD15FEV1** IMV (days)  0.040 0.018 0.026  
______________________________________________________________________________
IMV=intermittent mandatory ventilation, FiO2=fraction of inspired oxygen
*No=0, yes=1
**Results are from logistic regression analysis. Odds ratio is 1.041 (95% confidence interval 
for odds ratio is 1.005 to 1.078). Positive=1, negative=0.
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According to Spearman´s rank correlation test, PD15FEV1 values correlated with FEV1,
FEV1/FVC, FEF50, FEF75 and PEF values measured in the clinic (range of r = 0.36 - -0.58;
p<0.05 for all). Diurnal PEF variation correlated inversely with FEV1, FVC, FEF50 and PEF
values measured in the clinic (range of r = -0.36- -0.42; p<0.05 for all). A bronchodilator
response at home was inversely correlated with FEV1, FEV1/FVC, FEF50, FEF75 and PEF
values in the clinic (range of r = -0.32 - -0.41; p<0.05 for all) and in the clinic with FEF50 and
FEF75  values (range of r = -0.27 - -0.33; p<0.05 for both). According to Pearson´s
correlation, there were no significant correlations between birth weight in SD units and lung
function parameters.
In the group of schoolchildren born very preterm with respiratory symptoms, PD15FEV1
values tended to be lower than in children with no abnormal respiratory symptoms (p=0.07).
Other lung function values were similar in these two groups. Atopy had no effect on lung
function variables at school age. In the group of schoolchildren born very preterm whose
parent(s) smoked, PEF values in the clinic were significantly lower than in the group with
non-smoking parents (p=0.005). FEV1 and FVC values in the clinic tended to be
correspondingly lower (p=0.06 and p=0.08). In logistic regression analysis, bronchial
obstruction at school age was significantly associated with CLD and with parental smoking,
respectively (risk ratio 2.58, p=0.0002 and risk ratio 1.70, p=0.02).      
5.2. Effect of neonatal surfactant therapy on lung function at school age in children
born very preterm (Study II)
The ages of the children in the three different study groups (prophylactic, rescue and placebo
groups) were similar. The children in the rescue group were significantly shorter than the
controls, but between the other two groups there were no differences in height or weight. No
significant differences in the prevalence of atopy or parental smoking were observed between
the groups. 
Of the spirometric values, FVC and PEF were significantly lower among the children in the
placebo group than in any of the surfactant-treated children (p<0.05). The same parameters
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were significantly lower in the placebo group than in the prophylactic surfactant group
(p<0.05) (Figure 5). There were no significant differences in spirometric parameters between
the prophylactic and the rescue groups, or between the patients in the three trials. 
All spirometric parameters (FVC, FEV1, PEF and FEF50) were significantly lower in the
preterm cohort than in the controls (p<0.05), except FVC in the prophylactic group. As
compared with the values for the controls born at term and for the children with or without a
history of CLD, only the FVC values for the children without CLD were not significantly
reduced. All the other spirometric parameters were significantly lower in the preterm study
groups (p<0.001) (Figure 5). There was no significant difference between the groups in
∆FEV1: the median ∆FEV1 was 3.3% (-4.1 to 15.0%) in the prophylactic group, 5.0% (-3.8 to
29.1%) in the rescue group and 1.9%   (-3.0 to 14.7%) in the placebo group. During the 2
weeks of home spirometry monitoring, altogether 16 children (40%) had at least three
positive PEF responses to terbutaline (p between groups NS). Eight children (20%) had
abnormal diurnal PEF variation of A 20% at least four times during 4 weeks´ home
monitoring (p between groups NS). 
Neonatal factors associated with spirometric values in children
Multiple regression analysis was used to investigate the extent to which the lung function
parameters in these children were associated with neonatal factors (Table 8). To compensate
for the degree of prematurity, gestational age at birth was used as a covariate. The duration of
intubation and of surfactant supplementation explained 30 to 41% of the variability of FVC,
FEV1 and PEF. The impacts of surfactant supplementation and the duration of intubation
were additive. The duration of intubation was associated with the duration of oxygen therapy
and with the diagnosis of CLD: each of these three covariates
explained 15 to 30% of the variability of FVC, FEV1 or PEF (data not shown). Surfactant
supplementation explained about 10% of the variation in FVC, FEV1 and PEF. Surfactant
supplementation was also associated with a high SP-A/DPC ratio and short duration of A40%
inspired O2 therapy. The two latter variables were also associated with lung function
 (data not shown). Of the neonatal variables studied, only tracheobronchial stenosis in the
newborn was associated with low FEF50 in the children. In the present cohort of children 
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Figure 5. Study II. Spirometric values of the children measured in the clinic according to the
outcome in the different study groups of surfactant therapy as percentages of the reference
values. Medians are indicated by horizontal lines. Pr is prophylactic surfactant, Re rescue
surfactant, and Pl the placebo group; C, control group (children born at term). Study 1 (c; j,
with CLD) was a randomized trial of surfactant therapy in RDS. Study 2 (∆; [, with CLD)
was a double-blind study of prophylactic surfactant. Study 3 (d; l, with CLD) was a
placebo-controlled comparison between prophylactic and rescue surfactant therapy.
Significant differences between the placebo and the prophylactic surfactant groups are
indicated in the figure. Significant differences were also observed (p<0.05) between full-term
controls and the study groups except for FVC% between the controls and the prophylactic
group. i, controls. 
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who were small preterm infants, the degree of prematurity had no detectable association with
the lung function parameters. Neither the neonatal trial order nor the time of surfactant
supplementation had any influence on the association between the neonatal variables and the
spirometric values.
Table 8. Results of multiple regression analyses relating neonatal variables to lung 
function in childhood (subjects born before 30 weeks of gestation)* in the study II
___________________________________________________________________
Lung function    Regression p
parameter Covariates coefficient SE values 
   
___________________________________________________________________
FVC Duration of intubation (d) -0.24 0.062 0.004
Surfactant supplementation
(1=yes, 0=no) 13.14 4.98 0.012
FEV1 Duration of intubation (d) -0.23 0.062 0.0009
Surfactant supplementation 9.60 4.62 0.045
FEF50 Tracheo-bronchial stenosis
(1=yes, 0=no) -27.70 11.19 0.018
PEF Duration of intubation (d) -0.20 0.064 0.004
Surfactant supplementation 11.06 5.17 0.039
___________________________________________________________________
*Gestational age at birth was always included as a covariate; however, it was not 
significantly associated with the lung function parameters.
5.3. Peripheral blood lymphocyte subpopulations in schoolchildren born very 
preterm (Study III)
The 34 schoolchildren born very preterm and the 14 controls did not differ in age, height or
weight. In seven children (three preterm-born children and four control children) home
spirometry recording was not acceptable because of technical problems with the device (four
children) or non-compliance (three children). For the 34 preterm-born children screened, the
median (range) spirometric values in the clinic, expressed as percentages of the predicted
values, were: FVC 96 (39-121)%, FEV1 84 (39-105)%, PEF 74 (38-91)% and FEF50 70 (35-
110)%. In the control group, the corresponding median (range) spirometric values were: FVC
100 (84-124)%, FEV1 94 (79-118)%, PEF 86 (73-111)% and FEF50 106 (75-145)% of the
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predicted values. The schoolchildren born very preterm had significantly lower FEV1, PEF
and FEF50 values than the control group (p < 0.05). The median (range) of the number of
positive bronchodilator tests at home was 3 (0-8) in the preterm-born children and 0 (0-2) in
the control children (p = 0.0006). The median number (range) of abnormal PEF variations at
home was 1 (0-9) in the preterm-born children and 0 (0-1) in the control children (p = 0.006). 
Peripheral blood lymphocyte subpopulations
Flow cytometric measurements were obtained for all the control children and for 29 of the 34
children born preterm. Of these 29 preterm-born children, 14 had bronchial obstruction
without an earlier diagnosis of asthma. The percentages of peripheral blood CD4+ and CD8+
T lymphocytes expressing the activation marker CD25 were determined in 20 children born
very preterm. The percentage of CD4+ T lymphocytes and CD4/CD8 ratio were both
significantly lower in the children born very preterm, and the percentage of CD16+CD56
cells (NK cells) were significantly higher than in the healthy controls 
(p < 0.05). Otherwise, the percentages of lymphocyte subsets in the two groups were
comparable (Table 9).  
In all the children, significant negative associations were observed between the number of A
15% increments in PEF values after β2 agonist during home monitoring and the percentage of
CD4+ T lymphocytes (rs = -0.45, p = 0.008) and the CD4/CD8 ratio 
(rs = -0.50, p = 0.003) (Figure 6). In the very preterm-born schoolchildren with bronchial
obstruction, the number of A 15% increments in PEF values after the β2 agonist had a
significant negative association with the percentage of CD4+ T cells expressing CD 25 
(r = -0.75, p = 0.03) (Figure 6). In all children, the number of A 15% increments in PEF
values after the β2 agonist and the percentage of CD19+ lymphocytes expressing CD 23
tended to be associated (r = 0.30, p = 0.08). 
Serum markers of inflammation 
The number of blood eosinophils and the ECP and MPO values were measured in all the
children. Serum ECP values were significantly higher in the preterm-born schoolchildren than
in the healthy controls (p = 0.03). The number of blood eosinophils and the MPO values were
similar in the two groups (Table 10). Parental smoking and ECP values were not significantly
associated.  
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Table 9. Peripheral blood lymphocyte subsets in schoolchildren born very preterm and 
controls in the study III 
_______________________________________________________________________
Cell surface antigen Preterm-born children Healthy controls p 
N = 34 N = 14 values
_______________________________________________________________________
CD3 67.9 (54.8-78.9) 71.3 (60.9-78.2) 0.15
CD4 38.4 (25.7-52.5) 42.2 (35.8-53.1) 0.03
CD8 28.8 (18.7-37.6) 25.3 (17.5-36.3) 0.18
CD4/CD8 ratio 1.4 (0.8-2.2) 1.8 (1.0-2.6) 0.03
CD19 11.8 (5.2-25.8) 9.8 (6.9-17.0) 0.18
CD23 10.6 (4.3-20.4) 7.7 (2.6-22.4) 0.66
CD19/CD23 9.3 (3.6-20.3) 5.8 (2.4-12.4) 0.06
CD16+CD56 11.5 (3.8-21.5) 5.5 (4.0-18.0) 0.03
CD4/CD25 8.5 (5-14) 9.1 (7.5-11.2)*
CD8/CD25 3 (0-15) 2.4 (1.9-2.7)*
_______________________________________________________________________
Values of lymphocyte subsets are expressed as percentages of lymphocytes.
Values are expressed as medians (range). 
*The reference values for CD4/CD25 and CD8/CD25 are taken from the reference 
Gemou-Engesaeth et al 1994.
Table 10. Numbers of blood eosinophils and S-ECP and S-MPO levels in schoolchildren born
very preterm and controls in the study III
     
________________________________________________________________________
Preterm-born children Healthy controls p 
N = 34 N = 14 values
________________________________________________________________________
Blood eosinophils,109/l 0.25 (0.05-0.96) 0.15 (0.03-0.65) 0.3
Serum ECP, µg/l 6.1 (1.8-50.6) 2.9 (1.8-10.2) 0.03
Serum MPO, µg/l 238 (43-1065) 168 (127-320) 0.3
________________________________________________________________________
Values are expressed as medians (range). 
ECP=eosinophil cationic protein, MPO=myeloperoxidase.
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Figure 6. Study III. Relationship between the number of increments of A 15% after terbutaline
during home monitoring and (A) the percentage of CD4+ T cells, (B) the CD4/CD8 ratio in
26 very preterm-born children (j) and in 10 healthy controls born at term (c) and (C) the
percentage of CD4+ T cells expressing CD25 in 9 very preterm-born children with bronchial
obstruction (j).
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5.4. The effect of inhaled budesonide on basic lung function in schoolchildren born very
preterm (Study IV)
Patient selection for budesonide treatment
Of the 63 children screened, 21 (33%) met our criteria for a budesonide treatment trial and 18
completed the study. At entry, the median (range) spirometric values in the clinic were FVC
87 (67-121)%, FEV1 74 (51-95)%, PEF 65 (44-77)%, and FEF50 59 (35-103)% of the values
of predicted for these 18 children. The mean (SD) age and height of the 18 children studied 
were 10.1 (1.8) y and -0.3 (1.6) SD. 
Spirometry in the clinic
There were no statistically significant differences between the spirometric values at entry and
after placebo treatment. The spirometric values before and after each treatment periods did
not change during the 4 months treatment with budesonide; median FEV1 74% (51%-95%) to
74% (59%-92%), FVC 87% (67%-121%) to 90% (66%-120%) and FEF50 59% (35%-103%)
to 55% (29%-104%). The median PEF values in the clinic tended after budesonide treatment
to increase from 65% (44%-77%) to 66% (51%-91%) (p=0.07) (Table 11). The sum of the
symptom scores decreased significantly during treatment with budesonide (p<0.05) (Table
12).
Table 11. Spirometry in the clinic in the study IV
___________________________________________________________________
After After 1 mo After 4 mo p
Parameter Baseline placebo budesonide budesonide values
___________________________________________________________________
FVC 87 (67-121) 86 (64-131) 88 (66-131) 90 (66-120) p=0.3
FEV1 74 (51-95) 73 (55-96) 75 (55-99) 74 (59-92) p=0.5 
PEF 65 (44-77) 61 (48-86) 68 (52-92) 66 (51-91) p=0.07
FEF50 59 (35-103) 53 (35-94) 58 (42-89) 55 (29-104) p=0.7
___________________________________________________________________
Values are expressed as medians (range).
Lung function tests are expressed as percentages of the predicted values.
Spirometry at home and respiratory symptoms
A diurnal PEF variation of A 20% was found at least four times during the 4 weeks´ home
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monitoring in 10 of the study children (48%); the median (range) frequencies of diurnal PEF
variation A 20% were 3 (0-9) during the whole 4 weeks period, 2 (0-6) during the 2 weeks
terbutaline treatment and 1.5 (0-5) during the placebo treatment. None of the control children
had abnormal diurnal PEF variation, the median (range) frequencies of a diurnal PEF
variation A 20% in the control children being 0 (0-1) during 4 weeks home monitoring (p <
0.01). The long-term effects of terbutaline and placebo at home were evaluated by studying
the mean morning and evening FVC, FEV1 and PEF values. There were no significant differ-
ences in these parameters recorded at home during the 2 weeks terbutaline or placebo
treatments. Neither did the PEF variation differ between these two periods. The median
(range) frequencies of diurnal PEF variation A 20% during the whole 4 months study period
decreased significantly, from 1.5 (0-5) during the 2 weeks placebo treatment period to 0 (0-4)
during last 2 weeks of budesonide treatment (p<0.05). During the 4 months treatment with
budesonide, the median morning PEF level increased from 58% to 67% of that predicted
(p<0.01). Correspondingly, the median morning FEV1 level increased from 65% to 70% of
that predicted (p<0.05). In the median evening PEF and FEV1 and in the median morning
FVC, the increase was significant only after  treatment with budesonide for 1 month (<0.05
for all). During treatment with budesonide for 4 months, the median evening FVC values at
home did not change (Table 12).  
 
Table 12. Spirometry at home and respiratory symptoms in the study IV 
_______________________________________________________________________________
After After After 1 mo After 4 mo p
Parameter terbutaline placebo budesonide budesonide values
______________________(1)__________(2)____________(3)__________(4)________________
Symptom score 26 (0-106) 18 (0-119) 3 (0-86) 4 (0-104) 2 vs 3 p=0.02
PEF variation 2 (0-6) 1.5 (0-5) 0.5 (0-3) 0 (0-4) 2 vs 3 p=0.05
2 vs 4 p=0.02
Morning PEF 56 (28-94) 58 (36-95) 61 (36-100) 67 (43-94) 2 vs 3 p=0.008
2 vs 4 p=0.005
Evening PEF 59 (38-92) 59 (42-100) 66 (40-92) 67 (44-99) 2 vs 3 p=0.04
Morning FEV1 67 (49-83) 65 (46-90) 69 (44-95) 70 (48-89) 2 vs 3 p=0.01
2 vs 4 p=0.02
Evening FEV1 66 (50-85) 66 (49-91) 71 (53-96) 71 (57-86) 2 vs 3 p=0.02 
_______________________________________________________________________________
Values are expressed as medians (range).
Lung function tests are expressed as percentages of the predicted values.
Correlations
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Gestational age at birth correlated positively with the PEF increment after budesonide
treatment in the clinic (rs=0.54, p<0.05). Atopy was positively correlated with the increment
in mean PEF value at home (rs=0.48, p<0.05) but there was no correlation with smoking. The
diurnal variation in PEF recorded during the treatment period with placebo and the short-term
reversibility in response to terbutaline correlated significantly with the decrease in diurnal
PEF variation during budesonide treatment (rs = 0.90 and 0.53, respectively, p < 0.05 for both)
5.5. Reproducibility of home spirometry in children with newly diagnosed asthma 
(Study V)
The characteristics of the 110 children included in this study are presented in Table 13.
According to these lung function data, the study group comprised children with mild asthma.
The mean duration of home spirometry recordings was 24 days (Table 13). During this
period, the mean (SD) compliance in the home spirometry was 94% (7), range 63-100. The
mean (SD) difference between the calibration of the home spirometry before and after home
monitoring of spirometry was 1.7% (1.5), range 0-8%. 
Table 13. Characteristics of the asthmatic children studied (N = 110) in the study V
___________________________________________________________________
Mean SD Range
___________________________________________________________________
Age, yr 7.4 1.6 5.0-10.9
Height, cm 126.1 11.2 104.6-157.1
Weight, kg 27.5 8.0 16.3-52.2
Sex F 42 (38%)
M 68 (62%)
Duration of home recordings, d 23.6 7.2 7-43
FEV1 (% of pred) in the clinic 91.8 11.4 58.8-116.9
FVC (% of pred)  in the clinic 98.7 11.8 64.8-141.1
PEF (% of pred) in the clinic 83.7 13.4 58.1-130.5
___________________________________________________________________
pred = predicted
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The reproducibility of the home measurements was estimated by calculating the percentage of
home spirometry measurements that met levels of reproducibility @ 5% (ATS criteria), <10%
and <15%. Children were assigned to three categories according to age (5-6 years, 7-8 years
and 9-10 years), and to height (< 121 cm, 121-135 cm and 136-150 cm).
The mean (SD) percentage of reproducible spirometry measurements, according to the ATS
criterion was 76.5% (16.6), range 21-100% in the whole study population. The percentage of
reproducible home measurements was significantly lower at 5-6 years than at 9-10 years
(p=0.007) (Table 14). In the < 121 cm height group the percentage of reproducible spirometry
values was significantly lower than in the 136-150 cm height group (p=0.002), and in the
121-135 cm group lower than in the 136-150 cm group (p=0.03) (Table 14).
Table 14.  Age and height in relation to the percentage of reproducible home measurements
according to the criterion of ATS in the study V
_________________________________________________________________________
N Mean SD Anova Pairwise p
p comparisons values 
_________________________________________________________________________
Age, yr 5-6 51 72.8 18.6 0.02 5-6 vs 7-8 0.22
7-8 38 77.1 13.8 5-6 vs 9-10 0.007
9-10 21 84.5 13.7 7-8 vs 9-10 0.10
Height, cm <120 39 71.6 19.2 0.007 <121 vs 121-135 0.15
121-135 50 76.6 14.1 <121 vs 136-150 0.002
136-150 21 85.6 13.4 121-135 vs 136-150 0.03
All 110 76.5 16.6
_________________________________________________________________________
As expected, height was strongly correlated with age in the children (r=0.89, p<0.0001). In
regression analysis, age and height were included separately, and adding the two did not
significantly improve the prediction of the dependent variable. Both age and height showed
significant linear relations to the percentages of reproducible home spirometry measurements.
The regression lines estimated were: percentage of reproducible home measurements = 55.6 +
2.82 x age (year) and = 22.6 + 0.43 x height (cm). Baseline spirometry (PEF, FEV1 and FVC)
as litres correlated significantly with the percentages of reproducible home measurements (r =
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0.34, r=0.34 and r=0.37, respectively,  p<0.001 for all). However, no correlation was found
when the spirometry values were expressed as percentages of the values predicted according
to the level of bronchial obstruction. 
At the <10% level of reproducibility, the mean (SD) percentage of reproducible spirometric
measurements for the whole study population was 89% (12). In the 5- to 6-year age group (n=
51) the mean (SD), expressed as a percentage of the reproducible spirometry values, was
86.2% (14.1), in the 7- to 8-year group (n=38) 89.3% (9.1) and in the 9- to 10-year group
(n=21) 93.2% (10.4). The percentage of reproducible measurements in home spirometry was
significantly lower in the 5- to 6-year age group than in the 9- to 10-year age group (p=0.02).
Correspondingly, in the < 121 cm height group the percentage of reproducible spirometry
values was significantly lower than in the 136-150 cm height group (p=0.006) (Figure 7).
Using the level of reproducibility <15%, the mean (SD) percentage of reproducible
spirometry measurements was 95% (9) for the whole study population. In the 5- to 6-year age
group (n= 51) the mean (SD) percentage of reproducible spirometry values was 93.2% (10.8),
in the 7- to 8-year group (n=38) 95.5% (4.5) and in the 9- to 10-year group (n=21) 95.7%
(8.8). The differences between the age groups and height groups were no longer statistically
significant.
The correlations between age and height versus the percentage of reproducible home 
measurements were: r=0.28, p=0.004 and r=0.29, p=0.002 (ATS criteria), r=0.24, p=0.01 
and r=0.26, p= 0.007 (at the <10% level of reproducibility) and r=0.15, p=0.12 and r=0.18,
p=0.07 (at the <15% level of reproducibility) (Figure 7).
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Figure 7. Reproducible spirometry measurements at home: the level of reproducibility @5%
(the criterion of the American Thoracic Society), <10% and <15% as percentages of all
registered spirometric tests in all 110 children with newly diagnosed asthma related to the age
and height of the children.
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6. DISCUSSION
It is of concern to many that prematurity itself and CLD in particular lead to "second-class"
lungs in later childhood and adult life (Wohl 1990). For example, in our cohort of 63
schoolchildren born very preterm, respiratory symptoms, bronchial obstruction, bronchial
lability and increased bronchial responsiveness were common, regardless of CLD. More than
half the children with bronchial obstruction responded to a β2 agonist or had abnormal diurnal
PEF variation. The variability of the bronchial obstruction could be detected only by record-
ing PEF values at home for a prolonged period. Our cohort had significantly lower CD4+ T-
cell percentages and CD4/CD8 ratios than healthy controls. A relationship between bronchial
lability and imbalance of T-cell subpopulations was observed. Our results provide suggestive
evidence that bronchial lability in schoolchildren born very preterm has an immunological
basis. Inhaling of budesonide for 4 months had no significant effect on basic lung function in
our cohort. A significant but small decrease in bronchial lability and respiratory symptoms
was observed during this treatment. We also present evidence that the beneficial pulmonary
effects of neonatal therapy with natural surfactant extend into later childhood.
6.1. Methodological discussion
In the clinic, we used conventional flow volume spirometry, the bronchodilator test, the
dosimetric histamine challenge test and conventional methods to evaluate inflammatory
changes. At home, the children recorded lung function with a novel device, a computerized
home spirometer. Measuring pulmonary function throughout successive days provides infor-
mation that might be missed with the single "snapshot" obtained in the office. Home monitor-
ing is therefore an important way to measure changes in pulmonary function, both within a
day and from day to day. The presence of bronchial lability is reflected by reduced PEF
values during the early morning hours. Accordingly, a response to a β2 agonist may be
observed more frequently during home spirometry. Values of PEF tend to be lowest on
waking, and to reach maximal values between noon and early evening (Enright et al 1994).
During homemonitoring it is recommended to make measurements on rising and early
evening, and in addition one other measurement in the 
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early afternoon (Quanjer et al 1997). In our study measurements with the spirometer was
recorded only every morning and evening because of practical aspects. 
Many variables may affect the validity of lung function testing in children at home. Of these
variables, the reliability of lung function measurements, including compliance and the
reproducibility of the measurements, are all of crucial importance. Data on the reproducibility
of individual measurements are especially sparse, and we do not know at what age children
can perform spirometry reliably at home. It is known that absolute values of PEF obtained
with standard devices, such as mini-flow meters, may be inaccurate, especially in children
(Sly et al 1997). Conventional recordings of PEF in asthma performed with hand-held mini
PEF meters, as compared with devices with electronic storage capabilities, may overestimate
the number of recordings, containing a large number of retrospective and even invented data
(Chowienczyk et al 1994, Quirce et al 1995, Redline et al 1996, Verschelden et al 1996).
Some studies comparing simple PEF meters and devices with electronic storage capabilities
have shown that compliance decreased after 2 weeks of home monitoring (Redline et al 1996,
Verschelden et al 1996). Our methodological study of the reproducibility of home spirometry
in children suggests that the device used in our study is suitable for clinical studies. Most of
the 110 children with newly diagnosed mild asthma aged from 5 to 10 years could perform
reproducible spirometry tests during home monitoring, although there was wide individual
variation. This ability is related to the age and height of the child. However, a considerable
proportion of the tests do not meet the criteria of reproducibility. In order to improve the
reproducibility of home spirometry and study results, the non-reproducible measurements
should be excluded from the analysis. The overall compliance in home spirometry during the
3 weeks of recording for the present asthma study was excellent; 94% of the required tests
were performed. This new computerized home spirometer affords the following advantages:
(a) compliance control of spirometry and medication by recording the time of measurement
and inhalation of the drug, (b) control of the reproducibility and acceptability of measure-
ments and (c) the possibility to calibrate the device. In the present cohort of 63 schoolchildren
born very preterm, 89% of the measurements during home monitoring were acceptable
according to the ATS criteria. 
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6.2. Bronchial obstruction
The finding of bronchial obstruction in our CLD children agrees with earlier observations
(Smyth et al 1981, Bader et al 1987, Andreasson et al 1989, Northway et al 1990, Kleine et al
1990, Hakulinen et al 1990, Blayney et al 1991, Parat et al 1995, Hakulinen et al 1996,
Koumbourlis et al 1996, Jacob et al 1997, Jacob et al 1998, Gross et al 1998). In our children,
the level of obstruction was as remarkable as in the study of Jacob et al (1998), in which the
children selected resembled our cohort and were as premature as ours. As the numbers of very
preterm born survivors have increased, mild to moderate obstructive airway dysfunction at
school age has also been found in children without a history of CLD, as in our study
(Bertrand et al 1985, Galdes-Sebaldt et al 1989, Chan et al 1989c, Lebourges et al 1990,
Kleine et al 1990, Hakulinen et al 1996, Jacob et al 1997). The definition of CLD by Shennan
et al (1988), also used in the present study, seems to be a sensitive predictor of abnormal
pulmonary outcome in schoolchildren born very preterm; 83% of the CLD children had bron-
chial obstruction. However, bronchial obstruction was also observed in 31% of the non-CLD
children. 
We found that the degree of bronchial obstruction was associated with the duration of
mechanical ventilation and the duration of oxygen therapy. This suggests that the severity of
neonatal disease and/or the duration of the neonatal treatment influences pulmonary function
at school age. Prematurity alone was also a risk factor for abnormal pulmonary function in
our schoolchildren born very preterm. In agreement with earlier studies, our schoolchildren
born preterm without respiratory disease (RDS or CLD) had reduced FEV1, PEF and FEF50-75
values in comparison with healthy controls (Figure 2) (Coates et al 1977, Bertrand et al 1985,
Mansell et al 1987, Galdes-Sebaldt et al 1989, Parat et al 1995). In contrast to previous
studies (Bader et al 1987, Mansell et al 1987, Galdes-Sebaldt et al 1989, Chan et al 1989c),
birth weight and gestational age were not associated with pulmonary function, obviously
because of the narrow range of gestational ages in our children. In our study, reduced fetal
growth had no effect on lung function at school age. This study was not ideal for investigating
such a hypothesis, because the IUGR group was small, comprising only 11% of the children.
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In agreement with previous studies (McLeod 1996, Gross et al 1998), FVC was significantly
smaller in our CLD group than in the non-CLD and control groups. Because whole-body
plethysmographic measurements were not performed in the present series, it is not certain
whether these lower FVC values reflect smaller thoracic gas volumes or air trapping because
of the bronchial obstruction. 
6.3. Bronchial responsiveness and lability
In contrast to previous studies, we found that only one of our children showed a significant
response to a β2 agonist in the conventional bronchodilator test in the clinic. A weak response
(A 10%) was noted in 8% of our children, all but one in the CLD group. In a previous study
by Northway et al (1990), responsiveness of A 10% in the bronchodilator test was observed in
44% of the patients with a history of CLD as compared with our 22%. Andreasson et al
(1989) and Kleine et al (1990) found that in preterm born and ventilated children of school
age, after β2 agonist inhalation, ∆FEV1 was higher than in the reference group, regardless of
CLD. Bronchodilator responsiveness was observed twice as often in preterm children with
previous CLD (47%) as in preterm children without CLD (25%) or in the term control group
(21%) (Gross et al 1998). However, in our study during home monitoring, the bronchodilator
test was positive in 39% in CLD group and also in 40% of the non-CLD group. In addition,
16% of the CLD and 24% of the non-CLD group had increased diurnal PEF variation,
indicating bronchial lability. A significant response in the bronchodilator test and/or abnormal
diurnal PEF variation, bronchial lability, were observed in 48% of all children and in 66% of
the 29 children with verified obstruction. None of our control children had abnormal diurnal
PEF variation or a positive bronchodilator test during home monitoring. In our study
significantly more schoolchildren born preterm without a history of RDS and CLD had
bronchial lability than the healthy controls The explanation for discrepancy between the
results for bronchial responsiveness at home and in the clinic might be differences in the
study population and the fact that a response to a β2 agonist may be observed more frequently
during home monitoring.  
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We found that CLD children were significantly more responsive to histamine than non-
CLD children and healthy controls. In our study the primary explaining factor for bronchial
responsiveness was the duration of ventilator treatment. At school age, bronchial
hyperresponsiveness has been observed not only in children with CLD (Smyth et al 1981,
Northway et al 1990), but also in prematurely born children without CLD (Bertrand et al
1985, MacLuscy et al 1986, Galdes-Sebaldt et al 1989). In contrast to previous reports
(Northway et al 1990), we obtained data on respiratory symptoms from the majority of the
children with verified obstruction. In our study, there tended to be an association between res-
piratory symptoms and PD15FEV1 values. This suggests that bronchial responsiveness is of
clinical significance. Those children whose PD15FEV1 was < 1 mg were all symptomatic.
Similarly, Chan et al (1989c) reported a strong relationship between respiratory symptoms
and airway responsiveness. 
6.4. Pathogenesis leading to lung function abnormalities 
In asthma, bronchial hyperresponsiveness is associated with inflammation of the bronchial
mucosa. In children with CLD, however, this association has not been verified. In a pilot
study, we treated 18 children with bronchial obstruction, increased responsiveness to a beta2
agonist, and/or increased diurnal variation in PEF without earlier diagnosed asthma for 4
months with inhaled GC. In contrast to asthma, basic lung function in our selected group of
very preterm born schoolchildren was not significantly affected by budesonide treatment for 4
months, although both respiratory symptoms and diurnal PEF variation decreased during the
treatment. This finding suggests that lung function abnormalities in schoolchildren born very
preterm may be due to structural changes resulting from the early lung tissue injury and the
abnormal pattern of remodelling. Increased bronchial responsiveness and bronchial lability
may be aggravated by structural airway narrowing and may be a reflection of altered airway
calibre or airway wall thickness (Chan et al 1989a, Northway et al 1990). In our study,
spirometric values in the clinic showed a significant correlation with bronchial
responsiveness and bronchial lability. Airway obstruction in schoolchildren born very preterm
may be related to submucosal fibrosis, or hypertrophy, or hyperplasia of bronchial smooth
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muscles (Margraft et al 1991, Chan and Silverman 1993).
The persistent pulmonary dysfunction in children born very preterm may in part be due to 
an immunological mechanism. In our study, as compared with the healthy controls, the
schoolchildren born very preterm with lung immaturity had a significantly lower CD4+ T-cell
percentage and CD4/CD8 ratio. In addition, the NK-cell percentage and the S-ECP values
were significantly higher. A weak but significant negative association was observed between
the bronchial responsiveness in PEF after a β2 agonist during home monitoring and the CD4+
T-cell percentage and the CD4/CD8 ratio, suggesting a relation between bronchial lability and
imbalance of T-cell subpopulations. Our findings suggest that bronchial lability is associated
with alterations in the balance of T-cell subsets and possibly with abnormal CD4+ T-cell
function. 
It is known that CD4+ T lymphocytes are important regulators in the human immune system.
A low CD4/CD8 ratio is a hallmark of intense, chronic immune responses, such as allograft
rejection, graft-versus-host disease, and haemophilia (Amadori et al 1995). In asthma, the
CD4/CD8 ratio is constant and does not differ from that of non-asthmatic groups (Corrigan et
al 1988). The cause of imbalance in the CD4/CD8 ratio among very preterm born
schoolchildren is not known. It may be a consequence of lung injury during infancy. It could
also be a factor maintaining lung function abnormalities during childhood. Recent
observations by Amadori et al (1995) suggest that the CD4/CD8 ratio is genetically
controlled. It is possible that, in infants born very preterm, the early inflammatory process
leading to CLD and lung function abnormalities is more easily triggered in those individuals
who are genetically susceptible to a low CD4/CD8 ratio. Originally, CLD was observed
primarily in preterm infants with severe RDS who had been exposed to high oxygen
concentrations and positive airway pressures. In recent years, however, a less severe form of
CLD has frequently been observed in infants with mild initial RDS, if any. This change in the
clinical pattern suggests that additional risk factors differing from those associated with the
severity of acute neonatal respiratory disease are responsible for the development of lung
function abnormalities in susceptible infants (Rojas et al 1995). In the present study, ECP, but
not MPO, levels in peripheral blood were significantly higher in schoolchildren born very
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preterm than in controls. An increased serum level of ECP is considered to be a sign of
activation of eosinophils during an inflammatory process in the airways (Bousquet et al
1990). A possible explanation for 
the increased levels of blood ECP is parental smoking. Serum ECP values in young children
have been shown to be related to maternal smoking (Lodrup Carlsen et al 1998). However, in
our study parental smoking and ECP values did not have a significant positive association. 
The course of CLD is considered to have four overlapping stages representing early
inflammation, its resolution by the age of 1 month, repair and remodeling of acute lung
injury, largely completed at 1 year of age and finally lung growth and development (Kotecha
and Silverman 1998). Our results, however, provide, evidence that immunological
abnormality still persists at school age. According to previous intervention studies and the
present pilot study, the potential efficacy of inhaled GC in the treatment of CLD at school age
is modest. The development of new therapies will depend on the results of future studies of
this possibly chronic immunological process.  
6.5. Effect of surfactant treatment
Given the evidence that the long-term outcome at school age is related to prematurity itself,
rather than to acute lung injury alone, the prospects for preventive intervention of CLD in the
premature would appear to be restricted. However, we present evidence that the beneficial
pulmonary effects of natural surfactant therapy at birth extend into later childhood. Our
follow-up study of small preterm infants participating in randomized studies of exogenous
natural surfactant supplementation demonstrates that human surfactant given prophylactically
at birth or early in RDS significantly improves FVC and PEF values at school age. The
interpretation of the results is complicated because of the relatively small sample size and of
multiple comparison of the data. Because, among the treated infants, early deaths due to
respiratory failure were fewer than among the placebo-treated children (Hallman et al 1985,
Merritt et al 1986, Merritt et al 1991) the number of infants with severe lung function
abnormalities lost to follow-up was greater in the placebo-treated group. Therefore the
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present results are likely to underestimate the beneficial long-term effects of exogenous
surfactant. Multiple regression analysis further suggested that the factor primarily responsible
for the favourable outcome was exogenous surfactant. The improved pulmonary outcome of
the surfactant recipients may have been 
due to the immediate improvement in lung function, resulting in shorter exposure to high
levels of inspired oxygen and to high ventilatory pressures. Additionally, surfactant may
protect against development of airway epithelial lesions during artificial ventilation
(Robertson et al 1992) and may ameliorate hyperoxic lung injury (Fracica et al 1994). Both
barotrauma and hyperoxia cause significant lung and airway injury (Jackson et al 1990). In
the present study, a shorter duration of oxygen treatment (>40%) was significantly associated
both with surfactant supplementation at birth and with higher FVC and FEV1 values at school
age. The surfactant index, the SP-A/DPC ratio during the first day of life, which is known to
be associated with survival without CLD (Hallman et al 1991), was additionally found to be
significantly associated with surfactant therapy and with better lung function values at school
age. However, regardless of surfactant therapy, bronchial obstruction associated with
bronchial lability and increased bronchial responsiveness remain common in schoolchildren
born very preterm. Neonatal variables affecting the pulmonary outcome at school age
negatively were duration of intubation and of O2 therapy. Therefore, it is possible that
shortening and modifiying the assisted 
ventilation and O2 therapy by improved management practices or by preventive treatments
would further improve the pulmonary outcome in small preterm infants.
6.6 Lung function abnormalities in asthma and in schoolchildren born very preterm:
risk factors and immunological changes
The possible link between asthma-like lung function abnormalities and respiratory symptoms
in preterm born schoolchildren and asthma is unclear. In asthma, the most characteristic lung
function features are bronchial lability, including short-term changes in the airway calibre,
reversible airflow limitation, BHR and eosinophilic and lymphocytic airway inflammation.
CLD is defined as a chronic disorder characterized by limitation of airflow that is partially
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reversible. It may be accompanied by BHR. The immunological changes, including the
present finding of imbalance in the CD4/CD8 ratio in the peripheral blood are different from
the findings reported in asthma. Atopy, the strongest identifiable factor predisposing to
asthma, was not a risk factor in lung function abnormalities in schoolchildren born very
preterm in the present study. On the ther hand, parental smoking associated significantly with
flow values at school age, increasing the risk of bronchial obstruction. Therefore, parental
smoking seems to predispose to lung function abnormalities of preterm children at school
age. 
Although asthma and CLD show some similarities, they are different disease entities (Figure
8). Cooccurrence of the two diseases is likely to occur and prematurity could be regarded as a
risk factor for asthma. In our study, 28% of the children in the CLD group and 16% in the
whole group of schoolchildren born very preterm had physician-diagnosed asthma. These
figures are considerably higher than the current asthma prevalence of 4-6% in Finland
(Koskela et al  1996). 
Figure 8. Simplified interrelationships between different lung disorders. Laryngotracheitis, wheezy
bronchitis, asthma and bronchiolitis are bronchial diseases. Interstitial lung disease and pneumonia
are lung parenchyma diseases. Chronic lung disease of children born very preterm, CLD and cystic
fibrosis have characteristics of both main disease groups.  
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7. SUMMARY
We evaluated basic spirometry, bronchial lability and responsiveness in a total of 63
schoolchildren born very preterm. Mean birth weight was 1044 g, mean gestational age 27.6
weeks and mean age at study 10.0 years. Eighteen children had a history of CLD. Forty of
these children, who were all born with an immature surfactant system before 30 weeks
gestation, had participated during infancy in trials of human surfactant therapy at the
Children´s Hospital, University of Helsinki, Finland. Thirty-four of these 40 children
participated in the follow-up study investigating the associations of lymphocytes or serum
inflammatory markers with obstructive lung disease and bronchial lability in schoolchildren
born very preterm. Eighteen of the 63 children born very preterm, who were without a
previous diagnosis of asthma but had bronchial obstruction and/or bronchial lability, were
selected for the budesonide trial. 
In a methodological study assessing the reproducibility of home monitoring in children with
newly diagnosed asthma, 110 outpatients born at term, at a mean age of 7.4 years, were
selected as our series for evaluating the reproducibility of home spirometry. 
In all the 63 schoolchildren born very preterm, flow-volume spirometry, a bronchodilator test
and home monitoring of PEF values twice daily for 4 weeks with and without a β2 agonist
were performed with a novel Data Storage Spirometer. The spirometric values in the office
and the results of home monitoring were compared with those for a control group of children
born at term (n=25). A histamine challenge test was performed in 29 schoolchildren born very
preterm and in 14 healthy controls. Eighteen of these prematurely born schoolchildren were
first treated with terbutaline inhalations for 4 weeks followed by inhaled placebo for the next
2 weeks, and then with inhaled budesonide for 4 months. Daily symptom scores, spirometric
values in the clinic and at home at the beginning and end of each treatment period, were
evaluated. We studied lymphocyte subsets in peripheral venous blood by flow cytometry in
29 children. Serum ECP and MPO levels, and the association between serum ECP and MPO
levels, lymphocyte subsets, and lung function were also determined. 
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In order to evaluate the reproducibility of home spirometry in children with newly diagnosed
asthma according to the criteria of the ATS, flow-volume spirometry was performed in 110
children in the clinic. Spirometric values were then monitored twice daily at home for 24 days
(mean). 
In the clinic spirometric values indicating bronchial obstruction were observed in 83% of
children in the CLD group and in 31% of children in the non-CLD group. Of the children
with obstruction, 62% reported respiratory symptoms during the past year. All spirometric
parameters except FEV1/FVC were significantly lower in the CLD group than in the non-
CLD group. All spirometric values were significantly lower in the preterm group than in the
full-term controls. Children without a history of RDS and CLD had significantly lower flow
values than the healthy controls. A significant response in the bronchodilator test and/or
abnormal diurnal PEF variation indicating bronchial lability were observed in 48% of the
children tested. The CLD children were significantly more responsive to histamine than the
non-CLD children and healthy controls. Bronchial obstruction was associated with the dur-
ation of mechanical ventilation and oxygen therapy. Parental smoking was a risk factor for
bronchial obstruction at school age. PEF and FVC values were higher in those schoolchildren
born very preterm who, during early infancy, had received surfactant compared with placebo.
In multiple regression analysis, the independent variables associated with higher spirometric
parameters were surfactant therapy and short intubation time after birth.
As compared with the healthy controls, the schoolchildren born very preterm had significantly
lower CD4+ T-cell percentages and CD4/CD8 ratios, whereas the NK-cell percentages and S-
ECP values were significantly higher. These very preterm born schoolchildren had
significantly lower spirometric values, except for FVC, than the control group. A weak, but
significant, negative association was observed between the bronchial responsiveness in PEF
after a β2 agonist during home monitoring and the CD4+ T-cell percentage and the CD4/CD8
ratio, indicating a relation between bronchial lability and imbalance of T-cell subpopulations.
After treatment with budesonide for 4 months, spirometric values in the clinic were not
significantly changed. 
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In our methodological study, the mean compliance in performing the spirometric tests at
home was 94%. In this study of newly diagnosed asthma in children aged 5 to 10 years, born
at term, the mean percentage of reproducible spirometric measurements was 77%, although
there was wide individual variation (range 21-100%). The percentage of reproducible home
measurements was significantly related to age and height of the children. We concluded that
most children aged 5 to 10 years can perform reproducible spirometric tests during home
monitoring, although there was wide individual variation. Younger children were less likely
to perform reproducible tests than were older children; almost all the children aged 9 years or
more, but also over half of the children aged 5-8 years, can perform reproducible spirometric
tests at home.  
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8. CONCLUSIONS
1. Respiratory symptoms, bronchial obstruction, bronchial lability and increased bronchial
responsiveness are common in schoolchildren born very preterm, regardless of CLD. Half the
children with obstruction responded to a β2 agonist or had abnormal diurnal PEF variation.
The variability of the bronchial obstruction could be detected only by recording PEF values at
home for a longish period. Bronchial obstruction was associated with the duration of
mechanical ventilation and oxygen treatment. Parental smoking was a risk factor for
bronchial obstruction at school age. A regular follow-up programme of lung function seems
to be essential throughout childhood including PEF monitoring at home especially children
with respiratory symptoms.
2. At school age, PEF and FVC values were significantly higher in those who received
surfactant compared with placebo during infancy, and in multiple regression analysis, the
independent variables associated with higher spirometric values were surfactant therapy and a
short intubation period after birth. This serves an evidence that the beneficial pulmonary
effects of natural surfactant therapy extend into later childhood. Our results suggest that
active prevention and treatment of lung function abnormalities during the perinatal period
prevent lung function abnormalities in children born very preterm. At school age, avoidance
of tobacco smoke, management of symptoms and heath maintenance are important . 
3. As compared with the healthy controls, the schoolchildren born very preterm with lung
immaturity had a significantly lower percentage of CD4+ T-cells and CD4/CD8 ratios,
whereas the NK-cell percentage and the S-ECP values were significantly higher. A weak but
significant negative association was observed between bronchial responsiveness in PEF after
a β2 agonist during home monitoring and the CD4+ T-cell percentage and the CD4/CD8 ratio,
suggesting a relationship between bronchial lability and imbalance of T-cell subpopulations.
Our results provide suggestive evidence for an immunological basis of bronchial lability in
schoolchildren born very preterm. The immunological changes, including the present finding
of imbalance in the CD4/CD8 ratio in the peripheral blood, are different from those reported
in asthma.
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Inhaled GC treatment for 4 months had no significant effect on basic lung function in our
selected group of very preterm born schoolchildren, although both respiratory symptoms and
diurnal PEF variation tended to decrease during the treatment. 
4. Most of the children with newly diagnosed mild asthma aged from 5 to 10 years can
perform reproducible spirometry tests during home monitoring, although there was wide
individual variation. The reproducibility improved with the age of the child. However, a
proportion of the tests did not meet the criteria of reproducibility. In order to improve the
reproducibility of home monitoring, the non-reproducible measurements should be excluded
from the analysis. 
85
9. ACKNOWLEDGMENTS
This study was carried out at the Allergy Unit of Skin and Allergy Hospital, University of Helsinki, between
1994 and 1998. Study children treated at the neonatal intensive care unit of the Hospital For Children and
Adolescents, University of Helsinki, were examined at school age at the Allergy Unit of Skin and Allergy
Hospital.
I am greatly indebted to Professor Jaakko Perheentupa, MD, Head of the Children´s Hospital and Professor
Kari Raivio, MD, Professor of Perinatology, University of Helsinki, for granting me permission to study
children born very preterm. I wish to express my sincere gratitude to Professor Annamari Ranki, MD, Head of
the Skin and Allergy Hospital, for giving me the opportunity to do this study at Skin and Allergy Hospital. I
express my sincere gratitude to Docent Tari Haahtela, MD, Head of the Allergy Unit of Skin and Allergy
Hospital, for placing the excellent research facilities of the hospital at my disposal. His support has been
extremely valuable. 
I would like to express my sincere thanks to Marja Tevaluoto-Aarnio, MD, who arouse my interest to study the
lung function of children born very preterm and introduced me to the fascinating field of pediatric pulmonology. 
My deepest gratitude I owe to Docent Markku Turpeinen, MD, my principal supervisor for his excellent advice
and support during this eventful work. His experience in the field of pediatric pulmonology has been 
fundamentally important for this work`s succesful completion. He also guided me into the world of scientific
work. I have learned from him a lot about the importance of a critical mind in scientific work. His patient
supervision, interest, and never-failing support made this study come true.
I also wish to express my special thanks to my second supervisor Professor Mikko Hallman, Head of the
Department od Pediatrics, University of Oulu, for his excellent advice and support during my work. His
experience in the field of science and profound knowledge on neonatal pulmonary diseases has been very
important for this work´s succesful completion. His optimistic attitude, help, and support, despite several duties,
has been invaluable. 
I would like to express my sincere thanks to Docent Kirsti Heinonen, MD and Docent Päivi Piirilä, MD, for
their most valuable criticism and advice during the preparation of the final manuscript of this thesis.   
I cordially thank all my collaborators. I owe thanks to Arja Hakulinen, MD, for help, encouragement and
cheerful company during these years and her participation in these trials. I sincerly thank Hanna Raitio, MD, 
and Kurt Nikander, BA, for their participation in these trials. Hanna Raitio, MD, Kirsi Järvinen, MD, and
Pamela Österlund, BA, are also acknowledged for their friendly advice and practical assistance in practicals of
flowcytometry. I also thank Docent Kaisu Juntunen-Backman, MD and other colleagues and friends at the
86
Allergy Unit of Skin and Allergy Hospital for interest and sympathy.
I owe many thanks to nursing staff of the study, Tuula Koljonen, Leena Ingelin-Kuortti and Ilona Kuistio for
skillfull assistance throughout the course of the study. Warm thanks are due to many colleagues and nurses at
the Allergy Unit of Skin and Allergy Hospital, University of Helsinki and other participating hospitals for their
assistance and positive attitude during these years. 
I am very grateful to Tuija Poussa, BA, for her skilful and friendly help and advice in statistical problems. I also
want to thank Jean Margaret Perttunen, for the language revision of the final manuscript of this thesis.  
All parents and children participarting in the study are warmly acknowledged. Without their positive attitude
towards research, this study could never have been accomplished. Special thanks are also due to healthy
subjects who participated in this study as volunteers. 
My very warmest thanks belong to my family, to Markku and our lovely children Aino, Jaakko, Tapani, Oili-
Maija, Ruut-Maaria and Anni-Kaisa. I thank for my husband and our children for all the love, understanding
and support I have received from them during the years of the study. You all are the best ones in my life.
Finally, I also want to thank my mother and father for care and love during my whole life. 
This work was financially supported by grants from the Foundation for Allergic Research, the Finnish Medical
Society Duodecim, The Finnish Society of Allergology and Immunology, the Foundation of Helsinki University
Central Hospital, the Orion Corporation Research Foundation and AstraZeneca R&D, Lund, Sweden.
Espoo, December 1999
Anna Pelkonen  
87
10. REFERENCES
Abbasi S, Bhutani VK, Gerdes JS. Long-term pulmonary consequences of respiratory distress syndrome in
preterm infants treated with exogenous surfactant. J Pediatr 1993;122:446-452.
Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia. Pediatr Clinics of
North America 1994;41:277-315.  
Ahlström H. Pulmonary mechanics in infants surviving severe neonatal respiratory insufficiency. Acta Paediatr
Scand 1975;64:69-80.
Ahrens P, Zielen S, Stöver B, Hofmann D, Ehrenberg A. Long-term pulmonary and allergic outcome of very
low birth weight prematures with and without BPD. Eur Respir J 1988;1(Suppl 1):7s (abstract).
Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, Clementi M, Chieco-Bianchi L.
Genetic control of the CD4/CD8 T-cell ratio in humans. Nature Med 1995;1:1279-1283.
American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies.
Official statement of the American Thoracic Society. Am Rev Respir Dis 1991;144:1202-1218.
American Thoracic Society. Standardization of spirometry--1994 Update. Am J Respir Crit Care Med
1995;152:1107-1136. 
Andreasson B, Lindroth M, Mortensson W, Svenningsen NW. Lung function eight years after neonatal
ventilation. Arch Dis Child 1989;64:108-113.
Arad I, Bar-Yishay E, Eyal F, Gross S, Godfrey S. Lung function in infancy and childhood following neonatal
intensive care. Pediatr Pulmonol 1987;3:29-33.
Arnon S, Grigg J, Silverman M. Pulmonary inflammatory cells in ventilated preterm infants: Effect of
surfactant treatment. Arch Dis Child 1993;69:44-48.
 
Arnon S, Grigg J, Silverman M. Effectiveness of budesonide aerosol in ventilator-dependent preterm babies:A
preliminary report. Pediatr Pulmonol 1996;21:231-235. 
 
Azzawi M, Bradley B, Jefferey OK, Frew AJ, Wardlaw AJ, Knowles G, Assoufi B, Collins JV, Durham S, Kay
AB. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am
88
Rev Respir Dis 1990;142:1407-1413.
Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent
infants with bronchopulmonary dysplasia. Pediatrics 1985;75:106-111.
  
Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, Epstein MF, Fitzhardinge PM, Hansen
CB, Hansen TN, Hodson WA, James LS, Kitterman JA, Nielsen HC, Poirier TA, Truog WE, Wung J-T. Is
chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987;79:26-
30.
Bader D, Ramos AD, Lew CD, Platzker ACG, Stable MW, Keens TG. Childhood sequelae of infant lung
disease: Exercise and pulmonary function abnormalities after bronchopulmonary dysplasia. J Pediatr
1987;110:633-639.
Bagchi A, Viscardi RM, Taciak V, Ensor JE, McCrea KA, Hasday JD. Increased activity of interleukin-6 but
not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of
bronchopulmonary dysplasia. Pediatr Res 1994;36:244-252. 
Ballard PL, Ballard RA, Planer BC et al. Plasma cortisol concentrations in premature infants. Pediatr Res
1996;39:A325(abstract).
Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary disease: Clinical presentation. J Pediatr
1979;95:819-823.
Baraldi E, Filippone M, Trevisanuto D, Zanardo V, Zacchello F. Pulmonary function until two years of life in
infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997;155:149-155.
Barker DP, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood
respiratory infection to adult lung function and death from chronic obstructive airway disease. BMJ
1991;303:671-675.
Beck JC, Mitzner W, Johnson JWC, Hutchins GM, Foidart J-M, London WT, Palmer AE, Scott R.
Betamethasone and the rhesus fetus: effect on lung morphometry and connective tissue. Pediatr Res
1981;15:235-240.
Bensky AS, Kothadia JM, Covitz W. Cardiac effects of dexamethasone in very low birth weight infants.
Pediatrics 1996;97:818-821.
89
Berner M, Gappa M, Hohenschild S, Dammann C, Bartmann P. Lung function at school-age in children
participating in a randomized surfactant trial (AlveofactR) for treatment of RDS. Pediatr Res 1996;39:326A
(abstract).
Bertrand J-M, Riley SP, Popkin J, Coates AL. The long-term pulmonary sequelae of prematurity: the role of
familial airway hyperreactivity and the respiratory distress syndrome. N Engl J Med 1985;312:742-745.
Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of
chronic lung disease. Arch Dis Child 1998;79:F26-F33.
Bhutani VK, Abbasi S, Long WA, Gerdes JS. Pulmonary mechanics and energetics in  preterm infants who had
respiratory distress syndrome treated with synthetic surfactant. J Pediatr 1992;120:18-24.
Blayney M, Kerem E, Whyte H, O´Brodovich H. Bronchopulmonary dysplasia: Improvement in lung function
between 7 and 10 years of age. J Pediatr 1991;118:201-206.
Bloomfield FH, Knight DB, Harding JE. Side effects of 2 different dexamethasone courses for preterm infants
at risk of chronic lung disease: A randomized trial. J Pediatr 1998;133:395-400.
Bonikos DS, Bensch KG, Northway WHJr, Edwards DK. Bronchopulmonary dysplasia: The pulmonary
pathologic sequel of necrotizing bronchitis and pulmonary fibrosis. Hum Pathol 1976;7:643-666. 
Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-
Lafontaine J, Godard P, Michel FB. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-1039. 
Bousquet J, Chanez P, Lacoste JY, Enander I, Venge P, Peterson C, Ahlstedt S, Michel F-B, Godard P. Indirect
evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of asthmatic
patients. J Allergy Clin Immunol 1991;88:449-460.
Brand PLP, Duiverman EJ, Postma DS, Waalkens HJ, Kerrebijn KF, van Essen-Zandvliet EEM, the Dutch
CNSLD Study Group. Peak flow variation in childhood asthma: relationship to symptoms, atopy, airway
obstruction and hyperresponsiveness. Eur Respir J 1997;10:1242-247.
Brozanski BS, Jones JG, Gilmour CH, Balsan MJ, Vazquez RL, Israel BA, Newman B, Mimouni FB, Guthrie
RD. Effect of pulse dexamethasone therapy in the incidence and severity of chronic lung diasease in the very
low birth weight infant. J Pediatr 1995;126:769-776. 
Bruce MC, Wedig K, Jentoft N, Martin RJ, Cheng PW, Boat TF, Fanaroff AA. Altered urinary excretion of
90
elastin crosslinks in premature infants who developed bronchopulmonary dysplasia. Am Rev Respir Dis
1985;131:568-572. 
Brundage KL, Mohsini KG, Froese AB, Walker CR, Fisher JT. Dexamethasone therapy for bronchopulmonary
dysplasia: Improved respiratory mechanics without adrenal suppression. Pediatr Pulmonol 1992;12:162-169.
Bryan MH, Hardie MJ, Reilly BJ, Swyer PR. Pulmonary function studies during the first year of life in infants
recovering from respiratory distress syndrome. Pediatrics 1973;52:169-178.
Cano A, Payo F. Lung function and airway responsiveness in children and adolescents after hyaline membrane
disease: a matched cohort study. Eur Respir J 1997;10:880-885.
Chan KN, Noble-Jamieson CM, Elliman A, Bryan EM, Aber VR, Silverman M. Airway responsiveness in low
birthweight children and their mothers. Arch Dis Child 1988;63:905-910.
Chan KN, Elliman A, Bryan E, Silverman M. Clinical significance of airway responsiveness in children of low
birthweight. Pediatr Pulmonol. 1989a;7:251-258. 
Chan KN, Elliman A, Bryan E, Silverman M. Respiratory symptoms in children of low birth weight. Arch Dis
Child 1989b;64:1294-1304.
Chan KN, Noble-Jamieson CM, Elliman A, Bryan EM, Silverman M. Lung function in children of low birth
weight. Arch Dis Child 1989c;64:1284-1293.
Chan KN, Silverman M. Increased airway responsiveness in children of low birth weight at school age: effect
of topical corticosteroids. Arch Dis Child 1993; 63:120-124.
Chan KN, Silverman M. Neonatal chronic lung disease and a history of asthma. Pediatr Pulmonol 1995;20:273-
275.
Chowienczyk PJ, Parkin DH, Lawson CP, Cochrane GM. Do asthmatic patients correctly record home
spirometry measurements? BMJ 1994;309:1618.
Chu J, Clemets JA, Cotton EK, Klaus MH, Sweet AY, Tooley WH. Neonatal pulmonary ischemia. Pediatrics
1967;40:709-782.
Clement A, Chadelat K, Sardet A, Grimfeld A, Tournier G. Alveolar macrophage status in bronchopulmonary
dysplasia. Pediatr Res 1988;23:470-473.
91
Cloutier MM, McLellan N. Nebulized steroid therapy in bronchopulmonary dysplasia. Pediatr Pulmonol
1993;15:111-116.
Co E, Chari G, McCulloch K, Vidyasagar D. Dexamethasone treatment suppresses collagen synthesis in infants
with bronchopulmonary dysplasia. Pediatr Pulmonol 1993;16:36-40.
Coates AL, Bergsteinsson H, Desmond K, Outerbridge EW, Beaudry PH. Long-term pulmonary sequelae of
premature birth with and without idiopathic respiratory distress syndrome. J Pediatr 1977;90:611-616.
Cole CH, Colton T, Shah BL, Abbasi S, MacKinnon B, Demissie S, Frantz ID. Early inhaled glucocorticoid
therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999;340:1005-1010.
Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an
international placebo-controlled trial. Pediatrics 1991;88:421-427.
Cooke R. The current use of exogenous surfactants in the newborn. Br J Obstet Gynaecol 1995;102:679-681.
Corbet A. Clinical trials of synthetic surfactant in the respiratory distress syndrome of premature infants. Clin
Perinatol 1993;20:737-760. 
Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet 1988;i:1129-1131.
Couser RJ, Ferrara TB, Ebert J, Hoekstra RE, Fangman JJ. Effect of exogenous surfactant therapy on dynamic
compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr 1990;
116:119-124.
Couser RJ, Ferrara TB, Wheeler W, McNamara J, Falde B, Johnson K, Hoekstra RE. Pulmonary follow-up 2.5
years after a randomized, controlled, multiple dose bovine surfactant study of preterm newborn infants. Pediatr
Pulmonol 1993;15:163-167.
Cummings JJ, D´Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for
bronchopulmonary dysplasia. N Engl J Med 1989;320:1505-1510.
Davis JM, Veness-Meehan K, Notter RH, Bhutani VK, Kendig JW, Shapiro DL. Changes in pulmonary
mechanics after the administration of surfactant to infants with respiratory distress syndrome. N Engl J Med
1988;319:476-479.
De Jong JW, Van der Belt-Gritter, Koeter GH, Postma PS. Peripheral blood lymphocyte cell subsets in subjects
92
with chronic obstructive pulmonary disease: association with smoking, IgE and lung function. Respir Med
1997;91:67-76. 
De Winter JP, van Sonderan L, van der Anker JN, Merth IT, Brand R, van Bel F, Zonderland HM, Quanjer
PhH. Respiratory illnesses in families of preterm infants with chronic lung disease. Arch dis Child
1995;73:F147-F52.
Duiverman EJ, Boer JAD, Roorda RJ, Rooyackers CMHM, Valstar M, Kerrebijn KF. Lung function and
bronchial responsiveness measured by forced oscillometry after bronchopulmonary dysplasia. Arch Dis Child
1988;63:727-732.
Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone on pulmonary mechanics and chronic lung
disease in very low birth weight infants: a randomized controlled trial. Pediatrics 1995;95:584-590.  
Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F. Mortality, severe respiratory distress
syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic
administration of the surfactant Curosurf. Pediatrics 1997;100:e4.
Elder DE, Hagan R, Evans SF, Benninger HR, French NP. Recurrent wheezing in very preterm infants. Arch
Dis Child 1996;74:F165-F171.
Enright PL, Lebowitz MD, Cockroft DW. Physiologic measures: pulmonary function tests. Am J Respir Crit
Care Med 1994;149:9-18.
  
Fok TF, Lam K, Dolovich M, Hg PC, Wong W, Cheung KL, So KW. Randomised controlled study of early use 
of inhaled corticosteroid in preterm infants with respiratory distress syndrome. Arch Dis Child 1999;80:F203-
F208.
Ford GW, Rickards AL, Kitchen WH, Lissenden JV, Ryan MM, Keuth CG. Very low birthweight and normal
birthweight infants: a comparison of continuing morbidity. Med J Aust 1986;145:125-128.
Fracica PJ, Caminiti SP, Piantadosi CA, Duhaylongsod FG, Crapo JD, Young SL. Natural surfactant and
hyperoxic lung injury in primates II. Morphometric analyses. J Appl Physiol 1994;76:1002-1010. 
Frank L. The use of dexamethasone in premature infants at risk for bronchopulmonary dysplasia or who already
have developed chronic lung disease: a caution note. Pediatrics 1991;88:413-414.
Fujiwara T, Chida S, Watabe YJ, Maeta H, Morita T, Abe T. Artificial surfactant therapy in hyaline-membrane
93
disease. Lancet 1980;1:55-59.
Galdes-Sebaldt M, Sheller JR, Grogaard J, Stahlman M. Prematurity is associated with abnormal airway
function in childhood. Pediatr Pulmonol 1989;7:725-729.
Garland JS, Alex CP, Pauly TH, Whitehead VL, Brand J, Winston JF, Samuels DP, McAuliffe TL. A three-day
course of dexamethasone therapy to prevent chronic lung diases in ventilated neonates: a randomized trial.
Pediatrics 1999;104:91-99. 
Gemou-Engesaeth V, Kay AB, Bush A, Corrigan AJ. Activated peripheral blood CD4 and CD8 T-lymphocytes
in childhood asthma: correlation with eosinophilia and disease severity. Pediatr Allergy Immunol 1994;5:170-
177.
Gemou-Engesaeth V, Bush A, Kay B, Hamid Q. Corrigan CJ. Inhaled glucocorticoid therapy of childhood
asthma is associated with reduced peripheral blood T cell activation and ´Th2-Type´cytokine mRNA
expression. Pediatrics 1997;99:695-703.
Gerdhard T, Herhe D, Feller R, Reifenberg L, Bancalari E. Serial determination of pulmonary function in
infants with chronic lung disease. J Pediatr 1987;110:448-456.
Gern JE, Eggleston PA, Schuberth KC, Eney ND, Goldstein EO, Weiss ME, Adkinson NF. Peak flow variation
in childhood asthma: A three-year analysis. J Allergy Clin Immunol 1994;93:706-716. 
Gibson AT, Pearse RG, Wales JKH. Growth retardation after dexamethasone administration: assessment by
knemometry. Arch Dis Child 1993;69:505-509.
Giffin F, Greenough A, Yuksel B. Does a family history of atopy influence lung function at follow-up of
infants born prematurely? Acta Paediatr 1995;84:17-21.
Goldman SL, Gerhardt T, Sonni R, Feller R, Hehre D, Tapia JL, Bancalari E. Early prediction of chronic lung
disease by pulmonary function testing. J Pediatr 1983;102:613-617.
Goldman SL, Bosque E, McCann E, Lewis K. Pulmonary mechanics in premature infants one month after
treatment with synthetic surfactant. J Pediatr 1992;120:25-28.
Goldsmith LS, Greenspan JS, Rubenstein SD, Wolfson MR, Shaffer TH. Immediate improvement in lung
volume after exogenous surfactant: Alveolar recruitment versus increased distention. J Pediatr 1991;119:424-
428.
94
Greenough A. Bronchopulmonary dysplasia: early diagnosis, prophylaxis, and treatment. Arch Dis Child
1990a;65:1082-1088.
Greenough A, Maconochie I, Yuksel B. Recurrent respiratory symptoms in the first year of life following
preterm delivery. J Perinat Med 1990b;18:489-494.
Grigg JM, Savill JS, Sarraf C, Haslett C, Silverman M. Neutrophil apoptosis and clearance from neonatal lungs.
Lancet 1991;338:720-722.
Groneck P, Reuss D, Goetze-Speer B, Speer CP. Effects of dexamethasone on chemotactic activity and
inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J
Pediatr 1993;122:938-944.
Groneck P, Gotze-Speer B, Oppermann M, Eiffert H, Speer ChP. Association of pulmonary inflammation and
increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential
analysis of inflammatory mediators in respiratory fluids of high risk preterm infants. Pediatrics 1994;93:712-
718. 
Groneck P, Gotze-Speer B, Speer CP. Effects of inhaled beclomethasone compared to systemic dexamethasone
on lung inflammation in preterm infants at risk of chronic lung disease. Pediatr Pulmonol 1999;27:383-387.
Groneck P, Speer CP. Inflammatory mediators and bronchopulmonary dysplasia. Arch Dis Child 1995;73:F1-
F3.
Gross SJ, Iannuzzi DM, Kveselis DA, Anbar RD. Effect of preterm birth on pulmonary function at school age:
A prospective controlled study. J Pediatr 1998;133:188-192. 
Hagan R, Minutillo C, French N, Reese A, Landau L, leSouef P. Neonatal chronic lung disease, oxygen
dependency and a family history of asthma. Pediatr Pulmonol 1995;20:277-283.
Hakulinen A, Heinonen K, Länsimies E, Kiekara O. Pulmonary function and respiratory morbidity in school-
age children born prematurely and ventilated for neonatal respiratory insufficiency. Pediatr Pulmonol
1990;8:226-232.
Hakulinen AL, Järvenpää A-L, Turpeinen M, Sovijärvi A. Diffusing capacity of the lung in school-aged
children born very preterm, with and without  bronchopulmonary dysplasia. Pediatr Pulmonol 1996;21:353-360. 
Halliday HL. Surfactant replacement therapy. Pediatr Pulmonol 1995;Suppl.11:96-97.
95
Hallman M, Merritt TA, Järvenpää A-L, Boynton B, Mannino F, Gluck L, Moore T, Edwards D. Exogenous
human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial.
J Pediatr 1985;106:963-969.
Hallman M, Merritt TA, Akino T, Bry K. Surfactant protein A, phosphatidylcholine and surfactant inhibitors in
epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome and outcome
in small premature infant. Am Rev Respir Dis 1991;144:1376-1384.
Hansen T, Corbet A. Lung development and function. Disorders of the transition. Chronic lung disease. In:
Taeusch HW, Ballard RA (eds) Avery´s Diseases of the Newborn. Respiratory system. W.B. Saunders
Company, pp 541-647,1998.
Harkavy KL, Scanlon JW, Chowdry PK, Grylack LJ. Dexamethasone therapy for chronic lung disease in
ventilator- and oxygen-dependent infants: a controlled trial. J Pediatr 1989;115:979-983.
Harrod JR, L´Heureux P, Wangensteen OD, Hunt CE. Long-term follow-up of severe respiratory distress
syndrome treated with IPPB. J Pediatr 1974;84:277-285.
Heneghan MA, Sosulski R, Baquero JM. Persistent pulmonary abnormalities in newborns: changing picture of
bronchopulmonary dysplasia. Pediatr Radiol 1986;16:180-184.
Hetzel MR, Clark TJH. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate.
Thorax 1980;35:732-738.
HiFi Study Group. High-frequency oscillatory ventilation compared with conventional mechanical ventilation in
the treatment of respiratory failure in preterm infants: assessment of pulmonary function at 9 months of
corrected age. J Pediatr 1990;116:933-941.
Hislop AA, Haworth SG. Pulmonary vascular damage and the development of cor pulmonale following hyaline
membrane disease. Pediatr Pulmonol 1990;9:152-161.
Holtzman RB, Frank L. Bronchopulmonary dysplasia. Clin Perinatol 1992;19.
Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy:
An observational study of neonates weighting 601 to 1300 grams at birth. Pediatrics 1993;92:191-196.
Howard E, Benjamins JA. DNA ganglioside and sulfatide in brains of rats given corticosterone in infancy, with
an estimate of cell loss during development. Brain Res 1975;92:73-87.
96
Hudak BB, Egan EA. Impact of lung surfactant therapy on chronic lung diseases in premature infants. Clin
Perinatol 1992;19:591-602. 
Jacob SV, Lands LC, Coates AL, Davis GM, MacNeish CF, Hornby L, Riley SP, Outerbridge EW. Exercise
ability in survivors of severe bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997;155:1925-1929.
Jacob SV, Coates AL, Lands LC, MacNeish CF, Riley SP, Hornby L, Outerbridge EW, Davis GM, Williams
RL. Long-term pulmonary sequelae of severe bronchopulmonary dysplasia. J Pediatr 1998;133:193-200.
Jackson RM. Molecular, pharmacologic and clinical aspects of oxygen-induced lung injury. Clin Chest Med
1990;11:73-83.
James AL, Pare PD, Hogg JC. The mechanics of airway narrowing in asthma. Am Rev Respir Dis
1989;139:242-246.
Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993;328:861-868.
Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a
3-year follow-up. Pediatrics 1995;96:897-906.
Kari MA, Heinonen K, Ikonen RS, Koivisto M, Raivio KO. Dexamethasone treatment in preterm infants at risk
for bronchopulmonary dysplasia. Arch Dis Child 1993;68:566-569.
Kari MA, Raivio KO, Venge P, Hallman M. Dexamethasone treatment of infants at risk for chronic lung 
disease: surfactant components and inflammatory parameters in airway specimens. Pediatr Res 1994;36:387-393.
Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, Jung AL, King K, Mueller D. Prophylactic
administration of calf lung surfactant extract is more effective than early treatment of respiratory distress
syndrome in newborns of 29 through 32 weeks´ gestation. Pediatrics 1993;92:90-98.
Kazzi NJ, Brans YW, Poland RL. Dexamethasone effects on the hospital course of infants with
bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics 1990;86:722-727.
Keeley FW, Fagan DG, Webster SI. Quantity and character of elastin in developing human lung parenchymal
tissues of normal infants and infants with respiratory distress syndrome. J Lab Clin Mef 1977;90:981-989.
Kelly E, Bryan H, Possmayer F, Frndova H, Bryan C. Compliance of the respiratory system in newborn infants
pre- and postsurfactant replacement therapy. Pediatr Pulmonol 1993;15:225-230.
97
Kelly YJ, Brabin BJ, Milligan P, Heaf DP, Reid J, Pearson MG. Maternal asthma, premature birth, and risk of
respiratory morbidity in schoolchildren in Merseyside. Thorax 1995;50:525-530.
Kendig J, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, Sinkin RA, Bartoletti A, Dweck HS,
Horgan MJ, Risemberg H, Phelps DL, Shapiro DL. A comparison of surfactant as immediate prophylaxis and
as rescue therapy in newborns of less than 30 weeks´ gestation. N Engl J Med 1991;324:865-871.
Kerstjens HAM, Brand PLP, de Jong PM, Koëter GH, Postma PS, the Dutch CNSLD Study Group. Influence
of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. Thorax
1994; 49:1109-1115.
Kitchen WH, Olinsky A, Doyle LW, Ford GW, Murton LJ, Slonim L, Callanan C. Respiratory health and lung
function in 8-year-old children of very low birth weight: a cohort study. Pediatrics 1992;89:1151-1158. 
Kleine MJK, Roos CM, Voorn WJ, Jansen HM, Koppe JG. Lung function 8-18 years after intermittent positive
pressure ventilation for hyaline membrane disease. Thorax 1990;45:941-946.
Konig P, Shatley M, Levine C, Mawhinney TP. Clinical observations of nebulized flunisolide in infants and
young children with asthma and bronchopulmonary dysplasia. Pediatr Pulmonol 1992;13:209-214.
Koops BL, Abman SH, Accurso FJ. Outpatient management and follow-up of BPD. Clin Perinatol
1984;11:101-122.
Koskela K, Haahtela T, Lahdensuo A, Muotka R, Ahonen E, Nurmi T, Vakkilainen E-L, Laitinen LA, Klaukka
T, Kukkonen E, Turpeinen M. Asthma programme in Finland 1994-2004. Clin Exp Al 1996;126:(Suppl 1)1-24. 
Kotecha S, Chan B, Azam N, Silverman M, Shaw RJ. Increase in interleukin-8 and soluble intercellular
adhesion molecule-1 in bronchoalveolar lavage fluid from premature infants who develop chronic lung disease.
Arc Dis Child 1995;72:F90-F96.
Kotecha S, Silverman M. Chronic respiratory complications of prematurity. In: Taussig LM, Landau LI (eds).
Pediatric Respiratory Medicine. Mosby Inc, pp 488-521, 1999.
Kothadia JM, O´Shea TM, Roberts D, Auringer ST, Weaver RG, Dillard RG. Randomized placebo-controlled
trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low
birth weight infants. Pediatrics 1999;104:22-27. 
Koumbourlis AC, Motoyama EK, Mutich RL, Mallory GB, Walczak SA, Fertal K. Longitudinal follow-up of
98
lung function from childhood to adolescence in prematurely born patients with neonatal chronic lung disease.
Pediatr Pulmonol 1996;2:28-34.
Kramer BM, Sinkin RA, Merzbach JL, Myers GJ, Brooks JG, Palumbo DR, Cox C, Kendig JW, Phelps DL.
Improved pulmonary outcome at school age with prophylactic surfactant administration. Pediatr Res 1995;
37:263A (abstract).
Lacoste JY, Bousquet J, Chanez P, Vyve T, Simony-Lafontaine J, Lequeu N, Vic P, Enander I, Godard P,
Michel FB. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive
pulmonary disease. J Allergy Clin Immunol 1993;92:537-548.
LaForce WR, Brudno S. Controlled trial of beclomethasone dipropionate by nebulization in oxygen- and
ventilator-dependent infants. J Pediatr 1993;122:258-258.
Lamarre A, Linsao L, Reilly J, Swyer PR, Levison H. Residual pulmonary abnormalities in survivors of
idiopathic distress syndrome. Am Rev Respir Dis 1973;108:56-61.
Langston C, Kida K, Reed M, Thurlbeck WM. Human lung growth in late gestation and in the neonate. Am Rev
Respir Dis 1984;129:607-613.
Lebourges F, Moriette G, Boule M, Delaperche MF, Relier JP, Gaultier C. Pulmonary function in infancy and
in childhood following mechanical ventilation in the neonatal period. Pediatr Pulmonol 1990;9:34-40.
Lebowitz MD. The use of peak expiratory flow rate measurements in respiratory disease. Pediatr Pulmonol
1991;11:166-174.  
Lin YJ, Yeh TF, Hsieh WS, Chi YC, Lin HC, Lin CH. Prevention of chronic lung disease in preterm infants by
early postnatal dexamethasone therapy. Pediatr Pulmonol 1999;27:21-26.
Lindroth M, Mortensson W. Long-term follow-up of ventilator-treated low birthweight infants. Acta Paediatr
Scand 1986;75:819-826. 
Lodrup Carlsen KC, Halvorsen R, Carlsen K-H. Serum inflammatory markers and effects of age and tobacco
smoke exposure in young non-asthmatic children. Acta Paediatr 1998;87:559-564.
Lucas A, Brooke OG, Cole TJ, Morley R, Bamford MF. Food and drug reactions, wheezing, and eczema in
preterm infants. Arch Dis Child 1990;65:411-415.
99
Macey MG. Immunophenotypic analysis of lymphocytes and leukaemias. In: Macey Marion G, editor. Flow
Cytometry. Clinical Applications. Oxford: Blackwell Scientific Publications. 1994:67-100.
MacLusky IB, Stringer D, Zarfen J, Smallhorn J, Levison H. Cardiorespiratory status in long-term survivors of
prematurity, with and without hyaline membrane disease. Pediatr Pulmonol 1986;2:94-102.
Mallory GBJr, Chaney H, Mutich RL, Motoyama EK. Longitudinal changes in lung function during the first
three years in prematurely born infants with moderate to severe bronchopulmonary dysplasia. Pediatr Pulmonol
1991;11:8-14.
Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with
bronchopulmonary dysplasia. Lancet 1983;i:1356-1358.
Mansell AL, Driscoll JM, James LS. Pulmonary follow-up of moderately low birth weight infants with and
without respiratory distress syndrome. J Pediatr 1987;110:111-115.
Marcgraft LR, Tomashefski JR, Bruce MC, Dahms BB. Morphometric analysis of the lung in BPD. Am Rev
Respir Dis 1991;143:391-400.
Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ, and the Group Health Medical
Associates. Asthma and wheezing in the first six years of life. N Engl J Med 1995;332:133-138. 
Matthes JWA, Lewis PA, Davies DP, Bethel JA. Birth weight at term and lung function in adolescence: no
evidence for a programmed effect. Arch Dis Child 1995;73:231-234.
McLeod A, Ross P, Mitchell S, Tay D, Hunter L, Hall A, Paton J, Mutch L. Respiratory health in a total very
low birthweight cohort and their classroom controls. Arch Dis Child 1996;74:188-194.
Merkus PJFM, Ten Have-Opbroek AAW, Quanjer PH. Human lung growth: A Review. Pediatr Pulmonol
1996;21:383-397.
Merritt TA, Stuard YD, Puccia J, Wood B, Edwards DK, Finkelstein J, Shapiro DL. Newborn tracheal aspirate
cytology: classification during respiratory distress syndrome and development of bronchopulmonary dysplasia.
J Pediatr 1981;98:949-956.
Merritt TA, Cochrane CG, Holcomb K, Bohl B, Hallman M, Strayer D, Edwards DK, Gluck L. Elastase and
alfa 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome: role of
100
inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest 1983;72:656-666.
Merritt TA, Hallman M, Bloom BT, Berry C, Benirschke K, Sahn D, Key T, Edwards D, Järvenpää A-L,
Pohjavuori M, Kankaanpää K, Kunnas M, Paatero H, Rapola J, Jääskeläinen J. Prophylactic treatment of very
premature infants with human surfactant. N Engl J Med 1986;315:785-790.
Merritt TA, Northway WH, Boynton BA. Bronchopulmonary dysplasia. Boston, Blackwell, 1988.
Merritt TA, Hallman M, Berry C, Pohjavuori M, Edwards DK, Jääskeläinen J, Grafe MR, Vaucher Y, Wozniak
P, Heldt G, Rapola J. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue
administration in very low birth weight infants with lung immaturity. J Pediatr 1991;118:581-594.
Merth IT, de Winter JP, Zonderland HM, Borsboom GJJM, Quanjer PH. Pulmonary function in infants with
neonatal chronic lung disease with or without hyaline membrane disease at birth. Eur Respir J 1997;10:1606-
1613.
Milner AD. How does exogenous surfactant work? Arch Dis Child 1993;68:253-254. 
Morley CJ, Greenough A. Respiratory compliance in premature babies treated with artificial surfactant (ALEC).
Arch Dis Child 1991;66:467-471.
Morray JP, Fox WW, Kettrick RG, Downes JJ. Improvement in lung mechanics as a function of age in the
infant with severe bronchopulmonary dysplasia. Pediatr Res 1982;16:290-294.
Motoyama EK, Fort MD, Klesh KW, Mutich RL, Guthrie RD. Early onset of airway reactivity in premature
infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1987;136:50-57.
Munshi UK, Niu JO, Siddiq MM, Parton LA. Elevation of interleukin-8 amd interleukin-6 precedes the influx
of neutrophils in tracheal aspirates from pretem infants who develop bronchopulmonary dysplasia. Pediatr
Pulmonol 1997;24:331-336. 
von Mutius E, Nicolai T, Martinez FD. Prematurity as a risk factor for asthma in preadolescent children. J
Pediatr 1993;123:223-229. 
Myers MG, McGuinness GA, Lachenbruch PA, Koontz FP, Hollingshead R, Olson DB. Respiratory illnesses in
survivors of infant respiratory distress syndrome. Am Rev respir Dis 1986;133:1011-1018.
Ng PC, Brownlee KG, Dear PRF. Gastroduodenal perforation in preterm babies treated with dexamethasone for
101
bronchopulmonary dysplasia. Arch Dis Child 1991;66:1193-1150.
Nickerson BG, Taussig LM. Family history of asthma in infants with bronchopulmonary dysplasia. Pediatrics
1980;65:1140-1144.
Nikolajev KN, Heinonen K, Hakulinen A, Länsimies E. Effects of intrauterine growth retardation and
prematurity on spirometric flow values and lung volumes at school age in twin pairs. Pediatr Pulmonol
1998;25:367-370.
Noble-Jamieson CM, Lukeman D, Silverman M, Davies PA. Low birth weight children at school age:
neurological, psychological, and pulmonary function. Semin Perinatol 1982;6:266-273.
Northway WH, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane
disease. N Engl J Med 1967;276:357-368.
Northway, WHJr, Moss RB, Carlisle KB, Parker BR, Popp RL, Pitlick PT, Eichler I, Lamm RL, Brown BWJr. 
Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 1990;323:1793-1799.
Northway WH. Bronchopulmonary dysplasia: 25 years later. Pediatrics 1992;89:969-973.
O´Brodovich HM, Mellins RB. Bronchopulmonary dysplasia. Am rev Respir Dis 1985;132:694-709.
Ogden BE, Murphy SA, Saunders GC, Pathak D, Johnson JD. Neonatal lung neutrophils and
elastase/proteinase inhibitor imbalance. Am Rev Respir Dis 1984;130:817-821.
O´Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with
chronic bronchitis: Inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med
1997;155:852-857.
O´Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG, Dillard RG. Randomized
placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator
dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics
1999;104:15-21.
The OSIRIS Collaborative Group. Early versus delayed neonatal administration of synthetic surfactant: the
judgment of OSIRIS. Lancet 1992;340:1363-1369. 
Palta M, Sadek M, Barnet JH, Evans M, Weinstein MR, McGuinness G, Peters ME, Gabbert D, Fryback D,
102
Farrell P for the newborn lung project. Evaluation of criteria for chronic lung disease in surviving very low birth
weight infants. J Pediatr 1998;132:57-63. 
Papile L-A, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, Krause-Steinrauf H, Verter J, Korones SB,
Lemons JA, Fanaroff AA, Stevenson DK. A multicentral trial of two dexamethasone regimens in ventilator-
dependent premature infants. N Engl J Med 1998;338:1112-1118. 
Pappagallo M, Bhutani VK, Abbasi S. Nebulized steroid trial in ventilator dependent preterm infants. Pediatr
Res 1991;29:327A
Parat S, Moriette G, Delaperche M-F, Escourrou P, Denjean A, Gaultier C. Long-term pulmonary outcome of
bronchopulmonary dysplasia and premature birth. Pediatr Pulmonol 1995;20:289-296.
Parker RA, Lindstrom DP, Cotton RB. Improved survival accounts for most but not all of the increase in BPD.
Pediatrics 1992;90:663-668.
Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch
Dis Child 1990;65:308-319.
Pelkonen AS, Nikander K, Turpeinen M. Jet nebulization of budesonide suspension into a neonatal ventilator
circuit: synchronized versus continuous nebulizer flow. Pediatr Pulmonol 1997;24:282-286.
Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr
Pulmonol 1995;19:371-378.
Pihkala J, Hakala T, Voutilainen P, Raivio K. Characteristics of recent fetal growth curves in Finland.
Duodecim 1989;105:1540-1546.
Pokriefka EM, Mehdizadeh B, Rabbani A. Inhaled flunisolide in bronchopulmonary dysplasia. Pediatr Res
1993;33:341A (abstract).
Polgar G, Promadhat V. Pulmonary function testing in children: Technics and standards. WB Saunders,
Philadelphia 1971;42-212.
Pramanik AK, Holtzman RB, Merritt TA. Surfactant replacement therapy for pulmonary disease. Ped Clin N
Am 1993;40:913-936.
Quanjer PH, Lebowitz MD, Gregg I, Miller MR, Pedersen OF. Peak expiratory flow: conclusions and
103
recommendations of a Working Party of the European Respiratory Society. Eur Respir J 1997;10(Suppl 24):2-8.
Quirce S, Contreras G, Dybuncio A, Chan-Yeung M. Peak expiratory flow monitoring is not a reliable method
for establishing the diagnosis of occupational asthma. Am J Respir Crit Care Med 1995;152:1100-1102.
Raghavender B, Smith J. Eosinophilic cationic protein in tracheal aspirates of preterm infants with
bronchopulmonary dysplasia. J. Pediatr 1997;130:944-947.
Raju TNK, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: A meta-analysis. J Pediatr
1993;123:603-610.
Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent
bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics 1996;98:205-210.
Redline S, Wright EC, Kattan M, Kercsmar C, Weiss K. Short-term compliance with peak flow monitoring:
results from a study of inner city children with asthma. Pediatr Pulmonol 1996;21:203-210.
Riedel F. Long term effects of artificial ventilation in neonates. Acta paediatr Scan 1987;76:24-29.
Riedel F, Achenbach U, Riegel CH. Prematurity and maternal hyperresponsiveness. J Perinat Med
1989;17:151-155.
Robertson B. Animal models of neonatal surfactant dysfunction. In: Robertson B, Van Golde LMG, Batenburg
JJ. Pulmonary Surfactant: from Molecular Biology to Clinical Practice. Amsterdam: Elsevier Science
Publishers, 1992:459-484.
Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Micro-aerosol administration of synthetic di-
palmitoyl lecithin in the respiratory distress syndrome: A preliminary report. Can Med Assoc J 1964;90:55-57.
Robinson DS, Bentley AM, Hartnell A, Kay AB, Durham SR. Activated memory T helper cells in
bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and
bronchial responsiveness. Pediatrics 1991;88:421-427.
Rojas MA, Gonzales A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology
and pathogenesis of neonatal chronic lung disease. J Pediatr 1995;126:605-610.
Rona RJ, Gulliford MC, Chinn S. Effects of prematurity and intrauterine growth on respiratory health and lung
function in childhood. BMJ 1993;306:817-820. 
104
Ryan G, Latimer KM, Dolovich J, Hargreave FE. Bronchial responsiveness to histamine: relationship to diurnal
variation of peak flow rate, improvement after bronchodilator, and airway calibre. Thorax 1982;37:423-429.
Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention
of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Ped Res 1994;36:122-128.
Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource
use in newborn infants weighing 500 to 1500 g. N Engl J Med  1994;330:1476-1480. 
Sears MR. Use of peak expiratory flow meters in adults: practical aspects. Eur Respir J  1997;10(Suppl 24):72-
74.
Seidman DS, Laor A, Gale R, Stevenson DK, Danon YL. Is low birth weight a risk factor for asthma during
adolescence? Arch Dis Child 1991;66:584-587.
Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature
infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527-532.
Shinwell ES, Karplus M, Zmora E, Reich D, Rothschild A, Blazer S, Bader D, Yurman S, Dolfin T, Kuint J,
Milbauer B, Kohelet D, Goldberg M, Armon Y, Davidson S, Sirota L, Amitai M, Zaretsky A, Barak M,
Gottfried S. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory
distress syndrome. Arch Dis Child 1996;74:F33-F37.
Shrivastava A, Lyon AJ, McIntosh N. Effect of dexamethasone on growth and bone mineralization in preterm
infants with chronic lung disease. Early Hum Dev 1998;51:A82 (abstract).
Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical
trials. Pediatrics 1990;86:728-736.
Sly PD. Relationship between change in PEF and symptoms: questions to ask in paediatric clinics. Eur Respir J
1997;10(Suppl 24):80-83. 
Smyth JA, Tabachnik E, Duncan WJ, Reilly BJ, Levison H. Pulmonary function and bronchial hyperreactivity
in long-term survivors of bronchopulmonary dysplasia. Pediatrics 1981;68:336-340.
Sobonya RE, Logvinoff MM, Taussig LM, Theriault A. Morphometric analysis of the lung in prolonged
bronchopulmonary dysplasia. Periatr Res 1982;16:969-972.
105
Soll RF, McQueen MC. Respiratory distress syndrome. In: Sinclair JC, Bracken MB, eds. Effective Care of the
Newborn Infant. Oxford: Oxford University Press 1992;325-358.
Sorva R, Perheentupa J, Tolppanen EM. New format for a growth chart. Acta Paediatr Scand 1984;73:527-529.
Sovijärvi ARA, Malmberg LP, Reinikainen K, Rytilä P, Håkan PA. Rapid dosimetric method with controlled
tidal breathing for histamine challenge. Chest 1993;104:164-170.
Speer CP, Ruess D, Harms K, Herting E, Gefeller O. Neutrophil elastase and acute pulmonary damage in
neonates with severe respiratory distress syndrome. Pediatrics 1993;91:794-799.
Speer CP, Silverman M. Issues relating to children born prematurely. Eur Respir J 1998;12(Suppl 27):13-16. 
Stahlman M, Hedvall G, Lindström D, Snell J. Role of hyaline membrane disease in production of later
childhood lung abnormalities. Pediatrics 1982;69:527-536.
Stocker JT. Pathology of long-standing "healed" BPD. Human Pathol 1986;17:943-961.
Stocks SJ, Godfrey S. The role of artificial ventilation, oxygen and CPAP in the pathogenesis of lung damage in
neonates: assessment by serial measurements of lung function. Pediatrics 1976;57:353-362. 
Stocks J, Godfrey S, Reynolds EOR. Airway resistance in infants after various treatments for hyaline membrane
disease: special emphasis on prolonged high levels of oxygen. Pediatrics 1978;61:178-183.
Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early
dexamethasone in high risk preterm infants. Arch Dis Child 1997;77:F185-F190.
Taghizadeh A, Reynolds EOR. Pathogenesis of BPD following HDM. Am J Pathol 1976;82:241-258. 
Tapia JL, Ramirez R, Cifuentes J, Fabres J, Hubner E, Bancalari A, Mercado E, Standen J, Escobar M. The
effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with
respiratory distress syndrome. J Pediatr 1998;132:48-52.
 
Tepper RS, Morgan WJ, Cota A, Taussig LM. Expiratory flow limitation in infants with bronchopulmonary
dysplasia. J Pediatr 1986;109:1040-1046.
Timonen KL, Nielsen J, Schwartz J, Gotti A, Vondra V, Gratziou C, Giaever P, Roemer W, Brunekreef B.
Chronic respiratory symptoms, skin test results, and lung function as predictors of peak flow variability. Am J
Respir Crit Care Med 1997;156:776-782.
106
Tomashefski JF, Opperman HC, Vawter GF. BPD: A morphometric study with emphasis on the pulmonary
vasculature. Pediatr Pathol 1984;2:469-487.
Van Lierde S, Smith J, Devlieger H, Eggermont E. Pulmonary mechanics during respiratory distress syndrome
in the prediction of outcome and differentiation of mild and severe bronchopulmonary dysplasia. Pediatr
Pulmonol 1994;17:218-224.
Venge P. Soluble markers of allergic inflammation. Allergy 1994;49:1-8.
Venge P, Roxin LE, Olsson I. Radioimmunoassay of human eosinophil cationic protein. Br J Haematol 
1977;37:331-335.
Verschelden P, Cartier A, L´Archevêque J, Trudeau C, Malo J-L. Compliance with and accuracy of daily self-
assessment of peak expiratory flows (PEF) in asthmatic subjects over a three month period. Eur Respir J 1996;
9:880-885.
Walti H, Boule M, Moriette G, Relier J-P. Pulmonary functional outcome at one year of age in infants treated
with natural porcine surfactant at birth. Biol Neonate 1992;61(Suppl 1):48-53.
Watterberg KL, Carmichael DF, Gerdes JS, Werner S, Backstrom C, Murphy S. Secretory leucocyte protease
inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J Pediatr 1994a;125:264-269. 
Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary
dysplasia. J Pediatr 1994b;125:264-269.
Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in
whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:210-215.
Watts CL, Bruce MC. Effect of dexamethasone therapy on fibronectin and albumin levels in lung secretions of
infants with bronchopulmonary dysplasia. J Pediatr 1992;121:597-607.
Weichsel ME. The therapeutic use of glucocorticoid hormones in the perinatal period. Potential neurological
hazards. Ann Neurol 1977;2:364-366.
Wensley DC, Silverman M. The quality of home spirometry in schoolchildren with asthma. Eur Respir J 1997;
10(Suppl 25):0318A (abstract).
Wilson DM, Baldwin RB, Ariagno. A randomized, placebo-controlled trial on effects of dexamethasone on
107
hypothalamic-pituitary-adrenal axis in preterm infants. J Pediatr 1988;113:764-768.
 
Wilson JW, Djukanovic R, Howarth PH, Holgate ST. Inhaled beclomethasone dipropionate downregulates
airway lymphocyte activation in atopic asthma. Am J Respir Crit Care Med 1994;149:86-90.
Wohl M-E. Bronchopulmonary dysplasia in adulthood. N Engl J Med 1990;323:1834-1836.
Wong YC, Beardsmore CS, Silverman M. Pulmonary sequelae of neonatal respiratory distress in very low
birthweight infants: a clinical and physiological study. Arch Dis Child 1982;57:418-424.
Yamamoto C, Kojima T, Hattori K, Nogi S, Imamura H, Tsubura A, Kobayashi Y. Eosinophilia in premature
infants: correlation with chronic lung disease. Acta Paediatr 1996;85:1232-1235.
Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature
infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr 1990;117:273-282.
Yeh TF, Lin YJ, Hsieh WS, Lin HC, Lin CH, Chen YJ, Kao HA, Chien CH. Early postnatal dexamethasone
therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a
multicenter clinical trial. Pediatrics 1997;100:715-716.
Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, Hsieh WS, Lien YJ. Early dexamethasone therapy in
preterm infants: a follow-up study. Pediatrics 1998:101(5).
URL:http://www.pediatrics.org/cgi/content/full/101/5/e7.
Yoder MCJr, Chua R, Tepper R. Effect of dexamethasone on pulmonary inflammation and pulmonary function
of ventilatior dependent infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1991;143:10441048.
Yuksel B, Greenough A, Green S. Lung function abnormalities at 6 months of age after neonatal intensive care.
Arch Dis Child 1991;66:472-476.
Yuksel B, Greenough A. Neonatal respiratory support and lung function abnormalities at follow-up. Respir
Med 1992a;86:97-100.
Yuksel B, Greenough A. Randomised trial of inhaled steroids in preterm infants with respiratory symptoms at
follow up. Thorax 1992b;47:910-913.
Yuksel B, Greenough A, Gamsu HR. Respiratory function at follow-up after neonatal surfactant replacement
therapy. Respir Med 1993;87:217-221.
108
Zimmerman JJ, Farrell PM. Advances and issues in bronchopulmonary dysplasia. Curr Prob Pediatr
1994;24:159-170.
